

Disclaimer:

The clinical trial data presented on this website is compiled from publicly available sources, including the Clinical Trials Registry – India (CTRI) <https://ctri.nic.in/>.

Lung Connect India Foundation does not claim ownership of the original data and does not independently verify its accuracy, completeness, or timeliness.

This information is provided solely for educational and informational purposes and should not be considered as medical advice or a substitute for professional consultation. We strongly encourage patients and healthcare professionals to refer to the original sources and consult relevant authorities before making any healthcare decisions.

Lung Connect India Foundation assumes no liability for any errors, omissions, or actions taken based on this data. If you believe any information requires correction, please refer to the official CTRI website or contact the respective clinical trial sponsors.

TRI No.	Public Title	Type of Trial	Recruitment Status	Health Condition	Basic Inclusion criteria (Click on View for more detail of criteria)	Intervention/Drug/Treatment Name	Location	Details of Trails
CTRI/2011/08/001942	A Study in Second Line Non Small Cell Lung Cancer	Interventional	Indian: Open to Recruitment	Non Small Cell Lung Cancer	Disease progression during or after one prior first-line platinum-based chemotherapy with or without maintenance therapy Stage IV Non-Small Cell Lung Cancer	Docetaxel + Ramucirumab	A.H. Regional Cancer Centre,ORISSA Bhagwan Mahaveer Cancer Hospital and Research Centre,RAJASTHAN Jaslok Hospital and Research Centre,MAHARASHTRA Jehangir Hospital,MAHARASHTRA Lakeshore Hospital and Research Center,KERALA Madurai Medical College and Government Rajaji Hospital,TAMIL NADU Narayana Hrudayalaya Institute of Medicine,KARNATAKA Rajiv Gandhi Cancer Institute and Research Ce Regional Cancer Centre,KERALA Tata Memorial Hospital,MAHARASHTRA	View
CTRI/2011/11/002104	This is a comparative study for the Etoposide 50 mg capsules manufactured with Etoposide 50 mg capsules of Mylan Inc. USA, in patients with small cell lung cancers under fasting condition.	BA/BE	Indian: Open to Recruitment	Cancer Patients (Small Cell Lung Cancer)	Patients already receiving etoposide and expected to receive at least two additional cycles at the same dose.	Etoposide 50 mg capsules	Central India Cancer Research Institute,MAHARASHTRA Jeevandeep Oncosurgical Hospital,GUJARAT Kailash Cancer Hospital and Research Centre,GUJARAT Life Research Centre,GUJARAT Mahavir Cancer Sansthan,BIHAR NRR Hospital,KARNATAKA Suyash Hospital,MADHYA PRADESH Vintage Hospital and Research Centre,GOA	View
CTRI/2012/02/002410	A Phase 2b study with study drug and carboplatin and paclitaxel for Subjects with Advanced Non-Small Cell Lung Cancer	Interventional	Indian: Open to Recruitment	Patients with advanced non-small cell lung cancer	Subjects must have either stage IIIB with pleural effusion or IV NSCLC with radiographically measurable disease (RECIST 1.1 criteria). Women non-smokers with stage IV NSCLC should be screened for EGFR mutation and if positive be excluded from the study and placed on an EGFR kinase inhibitor.	Tamibarotene Plus Paclitaxel and Carboplatin	Curie Manavta Cancer Centre,MAHARASHTRA Dr Kamakshi Memorial Hospital,TAMIL NADU G Kuppuswamy Naidu Memorial Hospital,TAMIL NADU M S Patel Cancer Centre, Shree Krishna Hospital,GUJARAT NIZAMS Institute of Medical Sciences,ANDHRA PRADESH Noble Hospital,MAHARASHTRA Orchid Nursing Home,WEST BENGAL Shatabdi Super Speciality Hospital,MAHARASHTRA	View
CTRI/2012/09/002972	To compare the blood levels of Pemetrexed in Non small cell lung cancer patients treated with Alimta and Pemgem	BA/BE	Indian: Open to Recruitment	Indian adult ChemoNaive Adenocarcinoma Non-small cell lung cancer	Patients with a histologic or cytologic diagnosis of Adenocarcinoma - NSCLC Stage IIIA, IIIB, or IV not amenable to curative treatment surgery or radiotherapy	PEMGEM (Dr. Reddys Lab) 500 mg/m2 IV over 10 minute	ACTREC Tata memorial centre,MAHARASHTRA	View
	A Phase III study to compare the safety and efficacy of Bevacizumab against Avastin, in Patients with Non-Small Cell Lung Cancer	Interventional	Indian: Open to Recruitment	Unresectable or Metastatic Non-Squamous Non-Small Cell Lung Cancer	Unresectable or Metastatic Non-Squamous Non-Small Cell Lung Cancer,	Bevacizumab_Intas	Acharya Harihar Regional Cancer Centre,ORISSA All India Institute of Medical Sciences,DELHI Amrita Institute of Medical Sciences,KERALA Apple Hospital,GUJARAT B. J. Govt. Medical College & Sassoon General Hospital,MAHARASHTRA Batra Hospital & Medical Research Centre,DELHI BGS Global Hospitals,KARNATAKA BIBI General Hospital and Cancer Centre,ANDHRA PRADESH City Cancer Centre,ANDHRA PRADESH Curie Manavata Cancer Centre,MAHARASHTRA Dr. Kamakshi Memorial Hospital Pvt. Ltd.,TAMIL NADU Dr. Rai Memorial Medical Centre,TAMIL NADU	

TRI No.	Public Title	Type of Trial	Recruitment Status	Health Condition	Basic Inclusion criteria (Click on View for more detail of criteria)	Intervention/Drug/Treatment Name	Location	Details of Trails
CTRI/2014/09/005042							HCG Bangalore Institute of Oncology,KARNATAKA HCG Cancer centre,GUJARAT Health Point Multispecialty Hospital,WEST BENGAL IPGMER and SSKM Hospital,WEST BENGAL King George Medical University (Erstwhile CSMMU),UTTAR PRADESH Life Care Hospital,KARNATAKA Netaji Subhash Chandra Bose Cancer Research Institute,WEST BENGAL Post Graduate Institute of Medical Education & Research,CHANDIGARH Prince Aly Khan Hospital,MAHARASHTRA Rajiv Gandhi Cancer Institute and Research Ce Rajiv Gandhi Government General Hospital & Madras Medical College,TAMIL NADU Regional Cancer Centre, Medical College Campus,KERALA S.S. Hospital and Research Centre,BIHAR Sparsh Hospitals & Critical Care Pvt. Ltd.,ORISSA Srinivasam Cancer Care Hospitals India Pvt. Ltd.,KARNATAKA Unique Hospital Multispecialty & Research Institute,GUJARAT	View
CTRI/2015/01/005348	Exercise for the management of the cancer-related fatigue in advanced lung cancer.	Interventional	Indian: Open to Recruitment	Diagnosis of advanced lung cancer (stage III&IV NSCLC), declared as	Diagnosis of advanced lung cancer (stage III&IV NSCLC), declared as unresectable by the multidisciplinary oncology team	Mixed exercises, which includes resistance exercises and aerobic exercises.	Physiotherapy Department, Tata Memorial Hospital,MAHARASHTRA	View
CTRI/2017/09/009954	A study to understand if different brands of the drugs Erlotinib or Gefitinib used in lung cancer give the same concentration in blood of patients and whether they can be used interchangeably.	Interventional	Indian: Open to Recruitment	Malignant neoplasm of main bronchus	1. Patients on erlotinib/gefitinib for advanced/metastatic non-squamous NSCLC 2. Patient should have received chemotherapy with taxanes or pemetrexed with platinum	Erlotinib - Tarceva Gefitinib- Iressa	ACTREC, Tata Memorial Centre ,MAHARASHTRA	View
CTRI/2017/04/008305	A study to Assess the Safety and Efficacy of Docetaxel Lipid Suspension (DLS) for Injection of Intas Pharmaceuticals Limited, India in Lung Cancer patients.	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	Patient with histologically/cytologically confirmed locally advanced or metastatic NSCLC after platinum therapy failure	DOCEAQUALIP 20/80 (DOCETAXEL LIPID SUSPENSION FOR INJECTION 20/80 mg/vial of Intas Pharmaceuticals Limited, India	Apollo Hospital,ANDHRA PRADESH Apollo Specialty Hospital,TAMIL NADU Apple Hospital,GUJARAT City Cancer Centre,ANDHRA PRADESH Dinanath Mangeshkar Hospital ,MAHARASHTRA Government Medical College and Hospital.,MAHARASHTRA Gujarat Cancer & Research Institute,GUJARAT HCG Hospital,KARNATAKA HCG manavata cancer center,MAHARASHTRA Medica Superspecialty Hospital,WEST BENGAL Postgraduate Institute of Medical Education and Research, CHANDIGARH Shatabdi Hospital ,MAHARASHTRA Sir Ganga Ram Hospital,DELHI SMS medical college and hospital,RAJASTHAN Sparsh Hospital,ORISSA Srinivasam Cancer Care Hospitals,KARNATAKA Unique Hospital Multi Specialty and Research Institute ,GUJARAT Vedanta Institute of Medical Sciences, Hematology Oncology Clinic ,GUJARAT	View
	A Study effect of	Interventional	Indian:	Lung cancer	Lung cancer patients having chronic	Aprepitant	Tata Memorial Hospital,MAHARASHTRA	

TRI No.	Public Title	Type of Trial	Recruitment Status	Health Condition	Basic Inclusion criteria (Click on View for more detail of criteria)	Intervention/Drug/Treatment Name	Location	Details of Trails
CTRI/2017/05/008691	Aprepitant(Medicine) on cough in patients of lung cancer	onal	Open to Recruitment	patients having chronic cough more than 2 weeks, on cough suppressant as per treating physician choice	cough more than 2 weeks, on cough suppressant as per treating physician choice,			View
CTRI/2019/02/017798	Study of treatment with Durvalumab or Placebo in patients with locally advanced and surgically non-removable Non-Small Cell Lung Cancer (Stage III) whose disease has not progressed after platinum-based chemotherapy and radiation	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	No progression following definitive, platinum-based, concurrent or sequential chemoradiation therapy	Durvalumab	Apollo Speciality Hospital,TAMIL NADU Manibhai Shivabhai Patel Cancer Centre,GUJARAT Shatabdi Hospital ,MAHARASHTRA Shettys Hospital ,KARNATAKA Shree Himalaya Cancer hospital and Research Institute,GUJARAT Sri Venkateshwara Hospital ,KARNATAKA Tata Medical Centre,WEST BENGAL V. S. Hospital,TAMIL NADU	View
CTRI/2019/09/021090	A Phase III Trial to Compare the Effectiveness, Safety and action of HD204 (study drug) in comparison to Avastin® in patients with Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer (cancer of the lungs)	Interventional	Indian: Open to Recruitment	Malignant neoplasm of lower respiratory tract, part unspecified	Histologically confirmed metastatic Stage IV or recurrent non-squamous non-small cell lung cancer (NSCLC) that is no longer amenable to curative surgery or local therapy. Tumors without EGFR mutation or ALK receptor alteration. Patients with unknown mutation status or known EGFR mutation or ALK receptor alteration may be included provided the corresponding targeted agent is not available and chemotherapy is the standard of care of the study center.	Arm A HD204 (Bevacizumab-biosimilar) Arm B EU-Avastin® (Bevacizumab)	Bhakti Vedanta Hospital and Research Institute,MAHARASHTRA Deenanath Mangeshkar Hospital & Research Centre,MAHARASHTRA HCG Manavata Cancer Centre,MAHARASHTRA Hemato Oncology Clinic Ahmedabad Pvt Ltd, (Vedanta institutâ, - of medical sciences),GUJARAT Medica Super Speciality,WEST BENGAL Nirmal Hospital Private Limited,GUJARAT Noble Hospital Pvt. Ltd,MAHARASHTRA S7 Clinical Research Centre Pvt.Ltd,MAHARASHTRA Sujan Surgical Cancer Hospital & Amravati Cancer Foundation,MAHARASHTRA	View
CTRI/2019/08/020845	A study to check the efficacy of Osimertinib when given with Savolitinib in Patients with Lung Cancer who have progressed after Treatment with Osimertinib	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	EGFRm positive and MET positive Locally Advanced or Metastatic Non Small Cell Lung Cancer who have Progressed Following Treatment with Osimertinib The SAVANNAH Study	Osimertinib	Apollo Speciality Hospital, Chennai,TAMIL NADU Cytecare Cancer Hospital,KARNATAKA Rajiv Gandhi Cancer Institute,DELHI Tata Medical Centre,WEST BENGAL	View
CTRI/2019/11/021872	Addition of consolidative radiation therapy to TKI versus TKI alone in driver mutated lung cancer patients	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	1)Patients with positive oncogene driver mutation (EGFR or ALK/ROS) 2) Patients who have received at least 2-4 months of TKI therapy without progression	Local Consolidative Radiation therapy plus TKI	Tata Memorial Hospital,MAHARASHTRA	View
CTRI/2020/01/022617	Improving Performance status of Advanced lung cancer patients with Chemotherapy	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	Cytologically/pathologically confirmed NSCLC either stage 4 disease or those stage IIIC not amenable to definitive chemoradiation	Part 1: weekly paclitaxel,best supportive care Part 2 (for eligible patients): paclitaxel and carboplatin,best	All India Institute of Medical Sciences ,DELHI	View
CTRI/2020/03/023770	To Compare Carboplatin/ Paclitaxel with Cisplatin/ Etoposide in advanced Non	Interventional	Indian: Open to Recruitment	Malignant neoplasm of lower respiratory tract,	Stage III (IIIA/ IIIB/ IIIC) NSCLC, staged	Cisplatin and Etoposide with Radiotherapy	Dr.Akhil Kapoor,UTTAR PRADESH Tata Memorial Hospital,MAHARASHTRA	View
CTRI/2020/04/024761	Additional Consolidated radiation therapy after chemotherapy in limited metastatic lung cancer	Interventional	Indian: Open to Recruitment	Malignant neoplasm of overlappingsites of bronchus and lung	1) Patients who have received standard duration of systemic therapy (4 - 6 cycles) without progression of disease 2) Patients with 1-5 sites of metastatic disease not including the primary tumor and regional nodes	Local Consolidative Radiation therapy Standard Maintenance therapy	Tata Memorial Hospital,MAHARASHTRA	View
CTRI/2020/07/026870	A double-blind and placebo controlled clinical study conducted on patients with stage III or IVa Non-Small Cell Lung Cancer of investigational drug, CA170 in combination with Chemotherapy and Radiation Therapy at several clinical sites across India.	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	1. Histologically confirmed unresectable (Stage III or IVa) Non-Squamous NSCLC 2. Newly diagnosed	CA-170	All India Institute of Medical Sciences, New Delhi,DELHI Basavatarakam Indo American Cancer Hospital & Research Institute,TELANGANA Grant Medical Foundation Ruby Hall Clinic,MAHARASHTRA HCG Cancer Centre,KARNATAKA HCG NMR Curie Centre of Oncology,KARNATAKA Health Care Global Enterprises Limited,KARNATAKA KLES Dr. Prabhakar Kore Hospital and MRC,KARNATAKA KR Hospital,KARNATAKA	View

TRI No.	Public Title	Type of Trial	Recruitment Status	Health Condition	Basic Inclusion criteria (Click on View for more detail of criteria)	Intervention/Drug/Treatment Name	Location	Details of Trails
							Life line Diagnostic Centre cum Nursing Home,WEST BENGAL Shetty's Hospital,KARNATAKA Tata Medical Center, Kolkata,WEST BENGAL Tata Memorial Hospital, Mumbai,MAHARASHTRA	
CTRI/2020/09/027575	Study of efficacy of capmatinib in comparison with standard of care docetaxel as a second or third line therapy in participants with non-small cell lung cancers harboring MET exon 14 skipping mutation.	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	Progressed on one or two prior lines of systemic therapy for advanced/metastatic disease (stage IIIB/IIIC [not candidates for surgery, radiation or multi modality therapy] or IV NSCLC) and must be candidates for single agent chemotherapy (docetaxel)	Capmatinib (INC280) 150 mg or 200 mg	Christian Medical College,,TAMIL NADU Indraprastha Apollo Hospital,,DELHI Noble Hospital Clinical Research Department,MAHARASHTRA	View
CTRI/2020/08/027279	Role of upfront cranial radiotherapy in asymptomatic patients of brain metastases in lung cancer with positive mutations	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	Patients with positive oncogene mutation status (EGFR/ALK) Patients with radiologically confirmed parenchymal brain metastases Patients with asymptomatic Synchronous or Metachronous brain metastases	TKI alone	Tata Memorial Hospital,MAHARASHTRA	View
CTRI/2021/02/031568	COMPARISON EFFECT OF PANCHGAVYA GHRITA AND SWARASA IN LUNG CANCER	Interventional	Indian: Open to Recruitment	Other specified respiratory disorders	Diagnosed patients of Lungs Cancer, Alveoli cancer as per Radiology Diagnosed patients of Small Cell Lung Carcinoma & Non-Small Cell Lung Carcinoma as per Biopsy Patients of stage 1 as per TNM Classification	Panchgavya Swarasa	SHREE RMD AYURVED COLLEGE AND HOSPITAL,GUJARAT	View
CTRI/2021/01/030611	Study of Durvalumab or Placebo in Patients with Non-small Cell Lung Cancer (Stage II-III) who has residual disease after surgery and chemotherapy.	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	Histologically confirmed NSCLC with resectable stage II-III disease (according to IASLC Staging Manual in Thoracic Oncology v8.0) who have undergone curative intent therapy (complete resection of the primary tumor ± neoadjuvant and/or adjuvant therapy) per SoC. Select stage IIIB (ie, T3N2 or T4N2) patients will be eligible, provided they are upstaged to T3N2 or T4N2 based on confirmed pathology after surgery. Patients who are staged as T3N2 or T4N2 prior to surgery are not eligible.	Durvalumab	ACI Cumballa Hill Hospital,MAHARASHTRA All India Institute of Medical Sciences, Delhi ,DELHI Fortis Hospital Ltd, Bannerghatta Road,KARNATAKA HCG Manavata Cancer Centre,MAHARASHTRA HealthCare Global Enterprises Ltd ,KARNATAKA Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute,MAHARASHTRA Max Super Specialty Hospital, Mohali,CHANDIGARH Max Super Specialty Hospital, Shalimar Bagh,DELHI Mazumdar Shaw Medical Center (A unit of Narayana Health),KARNATAKA Rajiv Gandhi Cancer Institute and Research Center,DELHI Sir Ganga Ram Hospital,DELHI Tata Memorial Hospital, Mumbai,MAHARASHTRA	View
CTRI/2021/04/032961	Study of Neoadjuvant Osimertinib for the treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	Histologically or cytologically documented non-squamous NSCLC with completely resectable (Stage II -IIIB N2) disease (according to Version 8 of the IASLC Cancer Staging Manual 6 Complete surgical resection of the primary NSCLC must be deemed achievable, as assessed by a MDT evaluation (which should include a thoracic surgeon, specialised in oncologic procedures).	Osimertinib (TAGRISSO®) monotherapy	All India Institute of Medical Sciences, AIIMS,DELHI Kasturba Medical College and Hospital,KARNATAKA Mahamana Pandit Madan Mohan Malaviya Cancer Centre (MPMMCC),UTTAR PRADESH Rajiv Gandhi Cancer Institute and Research Center,DELHI Tata Medical Centre, Kolkata,WEST BENGAL Tata Memorial Hospital, Mumbai,MAHARASHTRA Thangam Hospital & Thangam Cancer Center,,TAMIL NADU	View
	A Phase IIb/III clinical trial to assess the safety and efficacy of study drug, CA-170 in combination with standard chemotherapy in stage IV lung cancer patients.	Interventional	Indian: Open to Recruitment	Malignant neoplasm of lower respiratory tract, part unspecified	Histologically documented, treatment-naïve Stage IV NonSquamous NSCLC (Version 8 of the International Association for the Study of Lung Cancer (IASLC) Staging Manual in Thoracic Oncology (Appendix E)	CA-170	7 Orange Hospital,MAHARASHTRA Abhishek Hospital,RAJASTHAN Acharya Vinoba Bhave Rural Hospital,MAHARASHTRA AIIMS,DELHI AIIMS Nagpur,MAHARASHTRA Amala Institute of Medical Sciences,KERALA American Oncology Institute,JAMMU & KASHMIR Amrita Institute of Medical Sciences ,KERALA	

TRI No.	Public Title	Type of Trial	Recruitment Status	Health Condition	Basic Inclusion criteria (Click on View for more detail of criteria)	Intervention/Drug/Treatment Name	Location	Details of Trails
CTRI/2021/10/037699							Apex Wellness Hospital ,MAHARASHTRA	View
							Asian Institute of Medical Sciences,HARYANA	
							B P Poddar Hospital & Medical Research Ltd,WEST BENGAL	
							Basavatarakam Indo American Cancer Hospital & Research Institute,TELANGANA	
							Binayak Multi-specialty Hospital,WEST BENGAL	
							Cancure Health Care LLP,MAHARASHTRA	
							Care Hospital,TELANGANA	
							Chandan Hospital,UTTAR PRADESH	
							Charnock Hospital,WEST BENGAL	
							Deenanath Mangeshkar Hospital and Research Centre,MAHARASHTRA	
							Department of Radiotherapy, Nil Ratan Sircar Medical College and Hospital ,WEST BENGAL	
							Dept of Medical Oncology, SMS Hospital,RAJASTHAN	
							Dharamshila Narayana Superspeciality Hospital,DELHI	
							Dr. B.L. Kapur Memorial Hospital,DELHI	
							Erode Cancer Centre,TAMIL NADU	
							Fortis Hospital Limited,UTTAR PRADESH	
							Fortis Hospital Shalimar Bagh,DELHI	
							Fortis Hospitals limited ,MAHARASHTRA	
							Fortis Hospitals limited Faridabad,HARYANA	
							Global Hospital & Research Institute,MAHARASHTRA	
							GMC Srinagar Super Speciality Hospital,JAMMU & KASHMIR	
							Grant Medical Foundation Ruby Hall Clinic,MAHARASHTRA	
							Gujarat Hospital " Gastro and Vascular Centre,GUJARAT	
							HCC Multispeciality Hospital LLP,GUJARAT	
							HCG Cancer Centre,KARNATAKA	
							HCG Cancer Centre,KARNATAKA	
							HCG City Cancer Centre,ANDHRA PRADESH	
							HCG Manavata Cancer Centre,MAHARASHTRA	
							HCG NMR Cancer Centre ,KARNATAKA	
							Himalayan Institute of Medical Science, Swami Rama Himalayan University,UTTARANCHAL	
							IMS and SUM Hospital,ORISSA	
							Jahangir Clinical Development Centre Private Ltd,MAHARASHTRA	
							K R Hospital, Mysore Medical College & Research Institute and Associated Hospitals,KARNATAKA	
							Kailash Cancer Hospital and Research Center ,GUJARAT	
							KGMU,UTTAR PRADESH	
							Kims Kingsway Hospitals,MAHARASHTRA	
							Kiran Hospital Multi Super Speciality Hospital and Research Center,GUJARAT	
							KLEs Dr. Prabhakar Kore Hospital & Medical Research Centre, ,KARNATAKA	
							Kolhapur Cancer Centre,MAHARASHTRA	
							Krupamayi Hospital,MAHARASHTRA	

TRI No.	Public Title	Type of Trial	Recruitment Status	Health Condition	Basic Inclusion criteria (Click on View for more detail of criteria)	Intervention/Drug/Treatment Name	Location	Details of Trails
							Lifeline Diagnostics Centre cum Nursing Home, WEST BENGAL	
							Mahatma Gandhi Cancer Hospital and Research Institute, ANDHRA PRADESH	
							Malabar Cancer Centre, KERALA	
							Medisquare Hospital & Research Institute, GUJARAT	
							Meenakshi Mission Hospital and Research Centre, TAMIL NADU	
							MNJ Institute of Oncology & Regional Cancer Centre, TELANGANA	
							Netaji Subhash Chandra Bose Hospital, WEST BENGAL	
							Omega Hospital, KARNATAKA	
							Omega Hospitals, ANDHRA PRADESH	
							Oncoville Cancer Hospital and Research Centre, KARNATAKA	
							Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, HARYANA	
							PDEAs Ayurved Rugnalaya and Sterling Multi-speciality Hospital, MAHARASHTRA	
							Punjab Cancer Care Multispeciality Hospital, PUNJAB	
							Regency Hospital Ltd, UTTAR PRADESH	
							Royapettah Government Hospital, Chennai, TAMIL NADU	
							RST Cancer Hospital and Research Centre, MAHARASHTRA	
							Saikrupa Hospital, MAHARASHTRA	
							Sanjeevani CBCC USA Cancer Hospital, CHHATTISGARH	
							Sankalp Speciality Hospital, MAHARASHTRA	
							Sapthagiri Institute of Medical Sciences and Research Centre, KARNATAKA	
							Shailya Hospital, GUJARAT	
							Sher -i- Kashmir Institute of Medical Sciences, JAMMU & KASHMIR	
							SP Medical College & AG of Hospitals, RAJASTHAN	
							Sparsh Hospital and Critical care, ORISSA	
							Sujan Surgicals Cancer Hospital, MAHARASHTRA	
							Taran Onco Care, MADHYA PRADESH	
							Tata Memorial Centre, MAHARASHTRA	
							Tirunelveli Medical college and Hospital, TAMIL NADU	
							Unique Hospital, GUJARAT	
							Valentis Cancer Care Hospital Pvt. Ltd., UTTAR PRADESH	
							Vydehi Institute of Medical Sciences and Research Centre, KARNATAKA	
	Phase III Global Study to Assess the Efficacy and Safety of Bevacizumab compared to Avastin in Combination with Carboplatin and Paclitaxel during Induction phase and Bevacizumab alone during the Maintenance phase in patients with Stage IIIB/IV Lung Cancer	Interventional	Indian: Open to Recruitment	Malignant neoplasm of lower lobe, bronchus or lung	1) Subjects with histologic or cytologic diagnosis of nsNSCLC with negative or unknown sensitizing epidermal growth factor receptor mutation and documented negative or unknown anaplastic lymphoma kinase translocation 2) .Subjects with newly diagnosed or recurrent Stage IIIB or IV ns NSCLC	BP01 (Bevacizumab)	Apex well ness Hospital, MAHARASHTRA	
							Apple Saraswathi Multispeciality Hospital, MAHARASHTRA	
							Basavatarakam Indoamerican Cancer Hospital and Research Institute, TELANGANA	
							Bharati Hospital, MAHARASHTRA	
							Chopda Medicare & Research Centre Pvt. Ltd, MAHARASHTRA	
							G B Vaghani Multispecialiry Hospital, GUJARAT	
							GBH Memorial Cancer Hospital, RAJASTHAN	
							Global Hospital, GUJARAT	

TRI No.	Public Title	Type of Trial	Recruitment Status	Health Condition	Basic Inclusion criteria (Click on View for more detail of criteria)	Intervention/Drug/Treatment Name	Location	Details of Trails						
CTRI/2021/10/037247							Halamma Kerudi cancer Hospital,KARNATAKA	View						
							HCG CANCER CENTER,ANDHRA PRADESH							
							HCG Cancer Centre,KARNATAKA							
							HCG City Cancer Centre,ANDHRA PRADESH							
							Indrayani Hospital & Cancer institute,MAHARASHTRA							
							Jubilee Mission Hospital,KERALA							
							Justice K S Hegde Charitable Hospital,KARNATAKA							
							Kamalnayan Bajaj Hospital,MAHARASHTRA							
							Kaushalya Medical Foundation Trust Hospital,MAHARASHTRA							
							Kingsway Hospital,MAHARASHTRA							
							Mahatma Gandhi Cancer Hospital & Research Institute,ANDHRA PRADESH							
							Malabar Cancer Centre,KERALA							
							Marathwada Cancer Hospital & Research Institute,MAHARASHTRA							
							MNJ Institute of Oncology & Regional Cancer Center,TELANGANA							
							Mumbai Oncocare Centre,MAHARASHTRA							
							MVR Cancer Centre & Research Institute,KERALA							
							Namco Charitable trusts SSGS Cancer Hospital,MAHARASHTRA							
							Narayana Multispeciality Hospital,GUJARAT							
							Natco Cancer Centre at Government General Hospital,ANDHRA PRADESH							
							Nirmal Hospital PVT LTD,GUJARAT							
							Noble Hospital Pvt Ltd,MAHARASHTRA							
							OncoVille Cancer Hospital and Research Centre,KARNATAKA							
							Rajalakshmi Hospital and Research Center,KARNATAKA							
							Regency Hospital LTD,UTTAR PRADESH							
							Regional Cancer Centre,KERALA							
							Royapettah Government Hospital,TAMIL NADU							
							Sai Cancer and Research Services Pvt. Ltd, MAHARASHTRA							
							Shalinitai Meghe Hospital & Research Centre,MAHARASHTRA							
							Shambhavi Centre for Cancer and Gynaecology,JHARKHAND							
							Shankus Hospitals,GUJARAT							
							Shashwat Haemato Onco Associates,GUJARAT							
							Sri Ramachandra Institute of Higher Education and Research,TAMIL NADU							
							Sterling Hospital,GUJARAT							
							Sunshine Global Hospital ,GUJARAT							
							Tirunelveli Government Medical college & Hospital,TAMIL NADU							
							Vedant Multispeciality Hospital,MAHARASHTRA							
							VGM Hospital,TAMIL NADU							
							Yenepoya University Medical College Hospital,KARNATAKA							
							HIPPOCAMPAL SPARING		Interventi	Indian:	Malignant	1) Histopathological proven Small Cell	Hippocampal	PGIMER,CHANDIGARH

TRI No.	Public Title	Type of Trial	Recruitment Status	Health Condition	Basic Inclusion criteria (Click on View for more detail of criteria)	Intervention/Drug/Treatment Name	Location	Details of Trails
CTRI/2021/10/037362	RADIOTHERAPY IN LUNG CANCER PATIENTS REQUIRING CRANIAL IRRADIATION	onal	Open to Recruitment	neoplasms of respiratory and intrathoracic organs	Lung Carcinoma. 2) Histopathological proven Non Small Cell Lung Carcinoma with BM. 3) Patient with BM with more than 5mm from hippocampus on CEMRI Brain	sparing radiotherapy technique in lung cancer patients receiving WBRT for prophylactic or therapeutic		View
CTRI/2022/04/041861	Clinical trial/study for lung cancer patients with ROS1 positive	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	1. Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIB/C, not amenable for radical treatment) or metastatic (Stage IV) NSCLC that harbors a documented ROS1 gene rearrangement 2. No prior treatment with a ROS1 tyrosine kinase inhibitor, chemotherapy, or other systemic therapy for advanced or recurrent (Stage IIIB/C not amenable for radical treatment) or metastatic (Stage IV) NSCLC	Entrectinib	All India Institute of Medical Sciences, DELHI Mahamana Pandit Madan Mohan Malaviya Cancer Centre, UTTAR PRADESH Mumbai Oncocare Centre (Unit of Cellcure Cancer Centre Pvt. Ltd.), MAHARASHTRA MVR Cancer Centre & Research Institute, KERALA Tata Medical Center, WEST BENGAL	View
CTRI/2022/02/040116	A Clinical study of Trastuzumab Deruxtecan as first line Treatment for Non-Small Cell Lung Cancer	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	1) .Histologically documented non-squamous Stage 3 locally advanced and unresectable NSCLC not amenable to treatment with curative intent (surgery or chemoradiotherapy) or Stage 4 or recurrent metastatic NSCLC. 2) .Participants must be treatment-naïve for palliative intent systemic therapy in locally advanced or metastatic disease and medically fit to receive first-line treatment. Prior local or systemic (neo-adjuvant or adjuvant) treatment for early-stage disease is permitted. 3). Documented qualifying HER2 exon 19 or 20 mutation (Appendix O lists qualifying activating HER2 exon 19 or 20 mutations)	Trastuzumab Deruxtecan (T-DXd)	Asian Institute of Gastroenterology Hospitals, TELANGANA HCG Manavata Cancer Centre, MAHARASHTRA Healthcare Global Enterprises Ltd., KARNATAKA Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, MAHARASHTRA Rajiv Gandhi Cancer Institute and Research Centre, WEST BENGAL Tata Memorial Hospital, MAHARASHTRA	View
CTRI/2023/03/050253	Study of efficacy and safety of JDQ443 in comparison with docetaxel in participants with non-small cell lung cancer.	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	1) Histologically confirmed locally advanced stage IIIB/IIIC (and not eligible for definitive chemo-radiation curative therapy or complete surgical resection) or stage IV previously treated NSCLC. Presence of a KRAS G12C mutation by central laboratory testing using tissue samples. 2) Participants have received one prior platinum-based chemotherapy and one prior immune checkpoint inhibitor therapy either in combination or in sequence.	JDQ443	Basavatarakam Indo American Cancer Hospital & Research Institute,, TELANGANA Fortis Hospital Ltd, KARNATAKA HCG Manavata Cancer Centre, MAHARASHTRA Mahatma Gandhi Cancer Hospital & Research Institute, ANDHRA PRADESH Netaji Subhas Chandra Bose Cancer Hospital, WEST BENGAL Rajiv Gandhi Cancer Institute and Research Centre, WEST BENGAL Somani Hospital, RAJASTHAN Tata Medical Centre, WEST BENGAL Tata Memorial Hospital, MAHARASHTRA	View
CTRI/2022/06/043460	Study of Durvalumab plus Domvanalimab in Stage III Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Concurrent Chemoradiation Therapy	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	1) locally advanced (Stage III), unresectable disease. 2) Documented EGFR and ALK wild-type status. 3) Participants must have received at least 2 cycles of platinum-based chemotherapy concurrent with radiation therapy, which must be completed within 1 to 28 days prior to the first dose of study intervention in the study	Arm A: Durvalumab plus Domvanalimab	Artemis Hospital, HARYANA Bhagwan Mahaveer Cancer Hospital & Research Centre, RAJASTHAN CARE Hospitals, Hyderabad, TELANGANA Cytecare Cancer Hospital, KARNATAKA Dr. B.L Kapur Memorial Hospital, DELHI HealthCare Global Enterprises Limited, KARNATAKA Mahamana Pandit Madan Mohan Malaviya Cancer Centre ,UTTAR PRADESH Max Superspecialty Hospital, Mohali, CHANDIGARH Narayana Superspecialty Hospital, Howrah, WEST BENGAL Rajiv Gandhi Cancer Institute and Research Centre, WEST BENGAL Sri Ram Cancer & Super Speciality Centre, RAJASTHAN Tata Medical Centre, Kolkata, WEST BENGAL Thangam Hospital and Thangam Cancer Centre, TAMIL NADU Vardhman Mahavir Medical College & Safdarjung Hospital, DELHI Zydus Cancer Centre, GUJARAT	View
	Study of Selpercatinib in Participants with Non-Small Cell Lung Cancer	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of	1) Must have histologically confirmed Stage IB, II, or IIIA NSCLC.	Selpercatinib	Cancer Relief Society's Rashtra Sant Tukdoji Charitable Cancer Hospital & Research Centre, MAHARASHTRA	

TRI No.	Public Title	Type of Trial	Recruitment Status	Health Condition	Basic Inclusion criteria (Click on View for more detail of criteria)	Intervention/Drug/Treatment Name	Location	Details of Trails
CTRI/2022/09/046009			nt	bronchus or lung	2). Must have an activating RET gene fusion in tumor based on polymerase chain reaction (PCR) or next generation sequencing (NGS).		HCG Manavata Cancer Centre,MAHARASHTRA Rajiv Gandhi Cancer Institute and Research Ce Regional Cancer Centre,KERALA Tata Memorial Hospital,MAHARASHTRA	View
CTRI/2022/08/045109	Clinical trial of metformin and valproic acid combination in lung cancer	Interventional	Indian: Open to Recruitment	Malignant neoplasm of middle lobe,bronchus or lung	Histologically or cytologically confirmed NSCLC, Stage III B or IV planned for palliative intent treatment with pemetrexed + carboplatin. Patients will be enrolled at baseline or within 3 weeks of cycle 1 of chemotherapy.	T.Metformin 1000 mg BD T.Valproate 20 mg/kg/day for 9 weeks in addition to chemotherapy	JIPMER Puducherry,PONDICHERRY	View
CTRI/2023/01/049349	Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecifiedpart of bronchus or lung	1). histologically or cytologically confirmed diagnosis of metastatic NSCLC that carries an ALK rearrangement 2) disease progression after alectinib or ceritinib as first line therapy	Lorlatinib	Bhaktivedanta Hospital & Research Institute,MAHARASHTRA Healthcare Global Enterprises Limited,KARNATAKA Medanta -The Medicity ,HARYANA Rajiv Gandhi Cancer Institute and Research Ce	View
CTRI/2024/01/061436	Study of efficacy and safety of JDQ443 as first-line treatment for patients with locally advanced or metastatic KRAS G12C- mutated non-small cell lung cancer with a PD-L1 expression 1% or a PD-L1 expression ≥ 1% and an STK11 co-mutation	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecifiedpart of bronchus or lung	1) Histologically confirmed locally advanced (stage IIIb/IIIc not eligible for definitive chemoradiation or surgical resection with curative intent) or metastatic (stage IV) NSCLC without previous systemic treatment for metastatic disease. Prior (neo)adjuvant treatment with chemotherapy and/or immunotherapy, or prior radiotherapy administered sequentially or concomitantly with chemotherapy and/or immunotherapy for localized or locally advanced disease are accepted if the time between therapy completion and enrollment is > 12 months. 2) Presence of a KRAS G12C mutation (all participants)	JDQ443	Amrita Institute of Medical Sciences,KERALA Caritas Hospital,KERALA JIPMER, Puducherry,TAMIL NADU Mahamana Pandit Madan Mohan Malaviya Cancer Centre,UTTAR PRADESH Tata Medical Centre,WEST BENGAL Tata Memorial Hospital,MAHARASHTRA	View
CTRI/2023/09/057267	Breathing Exercise improve the lung and cardiac functions in lung cancer patients.	Interventional	Indian: Open to Recruitment	Chronic obstructive pulmonary disease with acute lower respiratory infection	3 rd. stage -ECOG Lung Cancer Guidelines Lung Cancer patients under chemotherapy and medication	Diaphragmatic exercises	DR ANJIREDDY MULTI SPECIALTY HOSPITALS,ANDHRA PRADESH	View
CTRI/2023/08/056715	A study to evaluate immunotherapy pembrolizumab with chemotherapy in lung cancer patient.	Interventional	Indian: Open to Recruitment	Malignant neoplasm of lower respiratory tract, part unspecified	Subjects must have NSCLC, for adenocarcinoma EGFR, ALK negative mutated and must have been planned for palliative systemic therapy	Paclitaxel (175 mg/m2) with Platinum (Cisplatin-75 mg/m2 or Carboplatin AUC -5) OR Pemetrexed (500 mg/m2) with Platinum (Cisplatin-75 mg/m2 or Carboplatin AUC -5)	All India Institute of Medical Sciences,DELHI Bhagwan Mahaveer Cancer Hospital and Research Centre ,RAJASTHAN HOMI BHABHA CANCER HOSPITAL& RESEARCH CENTRE NEW CHANDIGARH, PUNJAB,CHANDIGARH Oncowin Cancer Center,GUJARAT Tata Memorial Hospital ,MAHARASHTRA	View
CTRI/2024/03/063500	Tislelizumab in Combination With Chemotherapy in First-line Treatment of Unresectable/Metastatic Non-small Cell Lung Cancer or Recurrent/Metastatic Squamous Cell Head and Neck Cancer	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecifiedpart of bronchus or lung Malignant neoplasm of head, face and neck	Locally advanced or recurrent NSCLC that is not eligible for curative surgery and or definitive radiotherapy with or without chemoradiotherapy, or metastatic nonsquamous or squamous NSCLC.	Tislelizumab	Indur Cancer Hospital,TELANGANA Pi Health Cancer Hospital,TELANGANA	View
	This is a clinical study to compare Dr Reddys developed nivolumab vs. nivolumab originator in patients with Advanced lung cancer who have failed with previous chemotherapy.	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecifiedpart of bronchus or lung	Patients with histologically- or cytologically-documented squamous cell NSCLC who present with Stage IIIB or Stage IIIC or Stage IV disease, or with recurrence or progressive disease following multimodal therapy Patients with known EGFR, and ALK genomic tumour aberrations should have disease progression on trait specific therapy for these aberrations prior to receiving nivolumab.	DRL_NU (DRL_Nivolumab)	Apollo Hospitals,TAMIL NADU Asirvatham Speciality hospital,TAMIL NADU Aster Medcity ,KERALA Basavatarakam Indo-American Cancer Hospital and Research Institute,TELANGANA Bharath Hospital & Institute of Oncology,KARNATAKA Chittaranjan National Cancer Institute,WEST BENGAL Deenanath Mangeshkar Hospital & Research Center,MAHARASHTRA Erode Cancer Centre Pvt Ltd ,TAMIL NADU Government Medical College,KERALA HCG Cancer Centre,ANDHRA PRADESH HCG City Cancer Centre ,ANDHRA PRADESH	

TRI No.	Public Title	Type of Trial	Recruitment Status	Health Condition	Basic Inclusion criteria (Click on View for more detail of criteria)	Intervention/Drug/Treatment Name	Location	Details of Trails
CTRI/2024/04/066248							HCG Manavata Cancer Centre ,MAHARASHTRA	View
							Jawaharlal Institute of Postgraduate Medical Education & Research(JIPMER),PONDICHERRY	
							Kailash Cancer Hospital and Research Center,GUJARAT	
							KLES Dr. Prabhakar Kore Hospital and MRC ,KARNATAKA	
							Maha mana Pandit Madan Mohan Malviya Cancer Centre,UTTAR PRADESH	
							Mahatma Gandhi Cancer Hospital and Research Institute,ANDHRA PRADESH	
							Mangalore Institute of oncology,KARNATAKA	
							Medanta "The Medicity" ,HARYANA	
							Meenakshi Mission Hospital and Research Centre,TAMIL NADU	
							MNJ Institute of Oncology and Regional Cancer Centre,TELANGANA	
							MVR Cancer Centre and Research Institute,KERALA	
							Nano Hospitals,KARNATAKA	
							Narayana Multispecialty Hospital,GUJARAT	
							Nizam's Institute of Medical Sciences (NIMS),TELANGANA	
							Omega Hospitals,ANDHRA PRADESH	
							Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences,HARYANA	
							Pi Health cancer Hospital,TELANGANA	
							R.K.Birla Cancer Centre SMS Medical College and attached hospital ,RAJASTHAN	
							Rabindranath Tagore International institute of cardiac sciences,WEST BENGAL	
							Radhakrishna Multispeciality hospital & IVF Centre,KARNATAKA	
							Rajiv Gandhi Cancer Institute and Research Ce	
							S.P. Medical College and AG Hospital,RAJASTHAN	
							Sankalp Speciality Hospital,MAHARASHTRA	
							Shalbay hospital,GUJARAT	
							Sparsh Hospital and Critical Care Pvt Ltd ,ORISSA	
							Sujan Surgicals Cancer Hospital and Amravati Cancer foundation,MAHARASHTRA	
							Taran Onco Care (A Unit of Taran Medi Care LLP),MADHYA PRADESH	
							Tata Memorial Hospital,MAHARASHTRA	
							Unique Hospital Multi speciality & Research Institute,GUJARAT	
							V.S. Hospitals,TAMIL NADU	
Vardhman Mahavir Medical College (VMMC) & Safdarjung Hospital,DELHI								
CTRI/2024/07/070802	First in Human Multicenter Open Name Dose-increase,Consolidation method to Study Safety drug-level in Blood & drug metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients with, without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary glands tumor	Interventional	Indian: Open to Recruitment	Malignant neoplasm of lower respiratory tract, part unspecified	EGFR Mutated Lung Cancer Patients with or without Brain Metastasis	JBI-778 Oral Capsule 40 mg daily dose in 21-day continuous cycles Once daily dosing in repeated 21-day cycles. JBI-778 capsule is taken orally with water approximately same time either 1 hour before a meal or 2 hours after a meal	All India Institute of Medical Sciences(AIIMS) ,DELHI	View
							Artemis Hospital,HARYANA	
							Erode Cancer Centre Private Limited,TAMIL NADU	
							HCG Manavata Cancer Centre,MAHARASHTRA	
							Oncoville Cancer Hospital and Research Center,KARNATAKA	
Tata Memorial Center,MAHARASHTRA								
	A study to examine pharmacokinetics, effectiveness, and safety of BAT3306 plus chemotherapy and compare with EU-Keytruda® and US-	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	1) Histologically/cytologically confirmed diagnosis of Stage IV (AJCC 8th edition) nsNSCLC. 2) Tumors without EGFR mutation/ROS1 rearrangement /ALK rearrangement.	BAT3306, EU-Keytruda®, and US-Keytruda®	Cancer Relief Society's RST Regional Cancer Hospital and Research Centre,MAHARASHTRA	
							Chittaranjan National Cancer Institute ,WEST BENGAL	

TRI No.	Public Title	Type of Trial	Recruitment Status	Health Condition	Basic Inclusion criteria (Click on View for more detail of criteria)	Intervention/Drug/Treatment Name	Location	Details of Trails
CTRI/2024/12/078579	KeytrudaA® in participants aged greater than or equal to 18 years with Stage IV non squamous non-small cell lung cancer						Chopada Medicare and research centre Pvt Ltd,MAHARASHTRA Dr. Ram Manohar Lohia Institute of Medical Sciences,UTTAR PRADESH GBH memorial cancer hospital,RAJASTHAN HCG Manavata Cancer Centre,MAHARASHTRA Hemato Oncology Clinic Ahmedabad Pvt Ltd,GUJARAT K R Hospital ,KARNATAKA KIMS- Kingsway Hospitals, SPANV Medisearch Lifesciences Private Limited,MAHARASHTRA Narayan Multispeciality Hospital (Unit of Narayan Hrudayalaya Limited),GUJARAT National Cancer Institute,MAHARASHTRA Nirmal Hospital Pvt Ltd,GUJARAT Regional cancer centre,KERALA Sparsh Hospitals & Critical Care Private limited,ORISSA State Cancer Institute, Indira Gandhi Institute of Medical Sciences,BIHAR Tata Memorial hospital,MAHARASHTRA	View
CTRI/2023/05/052218	Study of Datopotamab Deruxtecan (Dato-DXd) for first line treatment of patients with locally advanced or metastatic NSCLC	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	a) Is Stage IIIB or IIIC disease not amenable for surgical resection or definitive chemoradiation, or Stage IV metastatic NSCLC disease at the time of randomisation who have not received prior chemotherapy or other systemic therapy for first-line Stage IIIB, IIIC or IV NSCLC. Participants who have received prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for early stage disease (Stage I to IIIA) are eligible, provided that progression has occurred 6 months from the last dose of checkpoint inhibitor, chemotherapy, or other systemic anti-cancer therapy. b) Lacks sensitising EGFR tumour tissue mutation (eg, exon 19 deletion or exon 21 L858R, exon 21 L861Q, exon 18 G719X, or exon 20 S768I mutation), as well as ALK and ROS1 rearrangements. c) Has no documented tumour genomic alteration results in NTRK, BRAF, RET, MET or any other actionable driver oncogenes for which there are locally approved and available targeted first-line therapies.	Datopotamab Deruxtecan Durvalumab Carboplatin	All India Institute of Medical Sciences,DELHI Bhagwan Mahaveer Hospital and Research Centre,RAJASTHAN Jawaharlal Institute of Postgraduate Medical Education & Research,PONDICHERY Meenakshi Mission Hospital and Research Centre,TAMIL NADU MVR Cancer Hospital & Research Institute,KERALA Rajiv Gandhi Cancer Institute and Research Centre,DELHI Tata Medical Center, Kolkata,WEST BENGAL	View
CTRI/2024/10/075387	A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	Histologically or cytologically documented squamous or non-squamous NSCLC. Stage IV NSCLC not amenable to curative surgery or radiation. Absence of sensitizing EGFR mutations (including, but not limited to, exon 19 deletion and exon 21 L858R, exon 21 L861Q, exon 18 G719X, and exon 20 S768I mutations) and ALK and ROS1 rearrangements.	Experimental Arm-1 Volrustomig plus histology-specific chemotherapy (carboplatin plus either pemetrexed or paclitaxel) via IV infusion	Bharat Hospital and Institute of CARE Hospitals,TELANGANA HCG Manavata Cancer Centre ,MAHARASHTRA KIMS - KINGSWAY HOSPITALS,MAHARASHTRA Mahamana Pandit Madan Mohan Malviya Cancer Centre,UTTAR PRADESH Netaji Subhas Chandra Bose Cancer Hospital,WEST BENGAL NH-Rabindranath Tagore International Institute of Cardiac Sciences,WEST BENGAL Radhakrishna Multispeciality Hospital,KARNATAKA Rajiv Gandhi Cancer Institute and Research Centre,DELHI Vardham Mahavir Medical College and Safdarjung Hospital,DELHI	View
	A study of Repotrectinib versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor ROS1 positive Non-Small Cell Lung Cancer	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	1) Participants must not be exposed previously with TKIs that demonstrated activities in ROS1-positive NSCLC (eg, crizotinib, ceritinib, lorlatinib, brigatinib, entrectinib, ensartinib, DS605 1 b, NVL-520, taletrectinib, foretinib, and cabozantinib) 2) Participant has a ROS1 gene	Repotrectinib 40mg,160-mg capsules	All India Institutes of Medical Sciences,DELHI Artemis Hospital,HARYANA Fortis Memorial Research Institute,HARYANA HCG Cancer Centre,GUJARAT	

TRI No.	Public Title	Type of Trial	Recruitment Status	Health Condition	Basic Inclusion criteria (Click on View for more detail of criteria)	Intervention/Drug/Treatment Name	Location	Details of Trails
CTRI/2024/10/075224					<p>2) Participant has a ROS1 gene rearrangement or fusion as detected by a local test.</p> <p>3) confirmed diagnosis of locally advanced or metastatic NSCLC</p>		<p>Hemato Oncology Clinic Ahmedabad Pvt Ltd,GUJARAT</p> <p>Manipal Hospitals,KARNATAKA</p> <p>Nizams Institute of Medical Sciences,TELANGANA</p> <p>Rajiv Gandhi Cancer Institute & Research Centre,DELHI</p> <p>Regional Cancer Centre hospital ,KERALA</p> <p>Ruby Hall Clinic,MAHARASHTRA</p> <p>Sahyadri Super Speciality Hospital,MAHARASHTRA</p> <p>Sir H. N. Reliance Foundation Hospital and Research Centre,MAHARASHTRA</p> <p>Tata Memorial Centre,MAHARASHTRA</p>	View
	A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression $\geq 50\%$ or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression.	Interventional	Indian: Open to Recruitment	Non small Cell Lung Cancer		LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab	Rajiv Gandhi cancer institute and research centre (Dr Ulhas Batra)	
CTRI/2024/02/062974	Study which tests 2 medications (SB27, Keytruda) to compare how effective, safe and well tolerated in a large number of metastatic non-squamous non-small cell lung cancer patients.	Interventional	Total: Open to Recruitment Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	<p>1. Subjects who have a histologically confirmed or cytologically confirmed diagnosis of stage IV (M1a, M1b, or M1c of American Joint Committee on Cancer 8th edition) nonsquamous NSCLC.</p> <p>2. Subjects who have a documented PD-L1</p> <p>3. Subjects who have NOT received prior systemic therapy (including cytotoxic chemotherapy, targeted therapy, or antineoplastic biological therapy) for their metastatic NSCLC.</p>	SB27 (proposed pembrolizumab biosimilar)	<p>Deenanath Mangeshkar Hospital & Research Center,MAHARASHTRA</p> <p>Department of Radiation Oncology, AIIMS,ORISSA</p> <p>GBH General Hospital & GBH Memorial Cancer Hospital,RAJASTHAN</p> <p>HCG Cancer Centre,RAJASTHAN</p> <p>Healthcare Global Enterprises Limited,KARNATAKA</p> <p>Nizams Institute of Medical Sciences,TELANGANA</p> <p>R.K. Birla Cancer Centre,RAJASTHAN</p> <p>Sparsh Hospital & Critical Care (P) Ltd,ORISSA</p> <p>Sunshine Global Hospital,GUJARAT</p> <p>Tata Memorial Centre,MAHARASHTRA</p>	View
	This is a clinical study to compare Dr Reddy's developed nivolumab vs. nivolumab originator in patients with Advanced lung cancer who have failed with previous chemotherapy.	Interventional	Total: Open to Recruitment Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	<p>1. Patients with known EGFR, and ALK genomic tumour aberrations should have disease progression on trait specific therapy for these aberrations prior to receiving nivolumab.</p> <p>2. Patients with histologically- or cytologically-documented squamous cell NSCLC who present with Stage IIIB or Stage IIIC or Stage IV disease, or with recurrence or progressive disease following multimodal therapy (radiation therapy, surgical resection or definitive chemoradiation therapy for locally advanced disease). The diagnosis of disease indication should be by a biopsy which was excisional, incisional or core needle. Fine needle aspiration is considered as insufficient for confirmation of the diagnosis.</p> <p>3. Patients must have experienced disease recurrence or progression while on treatment or after at least one prior platinum doublet-based chemotherapy regimen for advanced or metastatic disease.</p>	DRL_NU (DRL_Nivolumab)	<p>Apollo Hospitals,TAMIL NADU</p> <p>Asirvatham Speciality hospital,TAMIL NADU</p> <p>Aster Medcity ,KERALA</p> <p>Basavatarakam Indo-American Cancer Hospital and Research Institute,TELANGANA</p> <p>Bharath Hospital & Institute of Oncology,KARNATAKA</p> <p>Chittaranjan National Cancer Institute,WEST BENGAL</p> <p>Deenanath Mangeshkar Hospital & Research Center,MAHARASHTRA</p> <p>Erode Cancer Centre Pvt Ltd ,TAMIL NADU</p> <p>Government Medical College,KERALA</p> <p>HCG Cancer Centre,ANDHRA PRADESH</p> <p>HCG City Cancer Centre ,ANDHRA PRADESH</p>	

TRI No.	Public Title	Type of Trial	Recruitment Status	Health Condition	Basic Inclusion criteria (Click on View for more detail of criteria)	Intervention/Drug/Treatment Name	Location	Details of Trails
CTRI/2024/04/066248							HCG Manavata Cancer Centre ,MAHARASHTRA	View
							Jawaharlal Institute of Postgraduate Medical Education & Research(JIPMER),PONDICHERRY	
							Kailash Cancer Hospital and Research Center,GUJARAT	
							KLES Dr. Prabhakar Kore Hospital and MRC ,KARNATAKA	
							Maha mana Pandit Madan Mohan Malviya Cancer Centre,UTTAR PRADESH	
							Mahatma Gandhi Cancer Hospital and Research Institute,ANDHRA PRADESH	
							Mangalore Institute of oncology,KARNATAKA	
							Medanta "The Medicity" ,HARYANA	
							Meenakshi Mission Hospital and Research Centre,TAMIL NADU	
							MNJ Institute of Oncology and Regional Cancer Centre,TELANGANA	
							MVR Cancer Centre and Research Institute,KERALA	
							Nano Hospitals,KARNATAKA	
							Narayana Multispecialty Hospital,GUJARAT	
							Nizam"s Institute of Medical Sciences (NIMS),TELANGANA	
							Omega Hospitals,ANDHRA PRADESH	
							Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences,HARYANA	
							Pi Health cancer Hospital,TELANGANA	
							R.K.Birla Cancer Centre SMS Medical College and attached hospital ,RAJASTHAN	
							Rabindranath Tagore International institute of cardiac sciences,WEST BENGAL	
							Radhakrishna Multispeciality hospital & IVF Centre,KARNATAKA	
							Rajiv Gandhi Cancer Institute and Research Center,DELHI	
							S.P. Medical College and AG Hospital,RAJASTHAN	
							Sankalp Speciality Hospital,MAHARASHTRA	
							Shalbay hospital,GUJARAT	
							Sparsh Hospital and Critical Care Pvt Ltd ,ORISSA	
							Sujan Surgicals Cancer Hospital and Amravati Cancer foundation,MAHARASHTRA	
							Taran Onco Care (A Unit of Taran Medi Care LLP),MADHYA PRADESH	
							Tata Memorial Hospital,MAHARASHTRA	
							Unique Hospital Multi speciality & Research Institute,GUJARAT	
							V.S. Hospitals,TAMIL NADU	
Vardhman Mahavir Medical College (VMMC) & Safdarjung Hospital,DELHI								
	A trial to learn if taking Osimertinib before and after chemotherapy and radiation therapy is safe and works in adults with non-small cell lung cancer (NSCLC) that cannot be treated with surgery	Interventional	Total: Indian: Not Yet Recruiting	Malignant neoplasm of bronchus and lung	2. Patients with histologically documented NSCLC of predominantly non-squamous, squamous, and adenosquamous pathology who present with locally advanced, unresectable (Stage III) disease (according to Version 8 of the IASLC Staging Manual in Thoracic Oncology). It is recommended but not required that except for overt cT4 disease, nodal status N2, or N3 should have been proven by biopsy, via endobronchial ultrasound, mediastinoscopy, thoracoscopy, or in absence of biopsy, should have been confirmed with whole body 18FDG PET plus contrast-enhanced CT in addition to	Osimertinib	Artemis Hospital,HARYANA	
							Hemato Oncology Clinic Ahmedabad Pvt. Ltd.,GUJARAT	
							Max Super Speciality Hospital,PUNJAB	
							Rajiv Gandhi Cancer Institute and Research Centre,DELHI	
							Sahyadri Superspeciality Hospital,MAHARASHTRA	

TRI No.	Public Title	Type of Trial	Recruitment Status	Health Condition	Basic Inclusion criteria (Click on View for more detail of criteria)	Intervention/Drug/Treatment Name	Location	Details of Trails
CTRI/2024/06/069176					<p>or in combination with PET.</p> <p>3. Patient who are eligible for and - planning to undergo CCRT or SCRT treatment.</p> <p>4. Patients who had recurred from Stage I/II/III after complete surgery or had gross incomplete resections can be included if they did not receive treatment with any chemotherapy, radiation therapy, immunotherapy, targeted therapy, or investigational agents.</p> <p>5. Availability of the EGFRm test results confirming that the tumour harbours one of the two common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations including de novo T790M</p>		Tata Memorial Centre,MAHARASHTRA	View
CTRI/2024/10/075244	Randomized, multicenter, double-blind, Phase 3 study investigating the safety and efficacy of dostarlimab plus belrestotug compared with pembrolizumab plus placebo in participants with previously untreated, unresectable, locally advanced or metastatic Non-small-cell lung cancer	Interventional	<p>Total: Open to Recruitment</p> <p>Indian: Open to Recruitment</p>	Malignant neoplasm of unspecified part of bronchus or lung	<p>1. A Locally advanced, unresectable NSCLC (not eligible for curative surgery and/or definitive radiotherapy with or without chemotherapy), or Metastatic NSCLC.</p> <p>2. Has not received prior systemic therapy.</p> <p>3. Has a PD-L1-high (TC $\geq 50\%$) tumor as determined by the VENTANA PD-L1(SP263) CDx Assay at a central laboratory.</p>	Dostarlimab plus Belrestotug	<p>All India Institute of Medical Science,N/A</p> <p>Apex Wellness Hospital,MAHARASHTRA</p> <p>Artemis Cancer Institute,DELHI</p> <p>Government Royapettah Hospital,TAMIL NADU</p> <p>Institute of Post Graduate Medical Education and Research,WEST BENGAL</p> <p>KLE Society s Dr Prabhakar Kore Hospital and Medical Research Centre,KARNATAKA</p> <p>Kolhapur Cancer Centre Private Limited ,MAHARASHTRA</p> <p>Radhakrishna Multispeciality Hospital and IVF Center ,KARNATAKA</p> <p>Sparsh Hospital & Critical Care Pvt Ltd,N/A</p> <p>Tata Memorial Hospital,MAHARASHTRA</p> <p>The Gujarat Cancer and Research Institute,GUJARAT</p> <p>Venkateshwar Hospital,DELHI</p> <p>Vydehi Institute of Medical Sciences and Research Centre,KARNATAKA</p>	View
CTRI/2024/07/070802	First in Human Multicenter Open Name Dose-increase,Consolidation method to Study Safety drug-level in Blood & drug metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients with, without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary glands tumor	Interventional	<p>Total: Not Applicable</p> <p>Indian: Open to Recruitment</p>	Malignant neoplasm of lower respiratory tract, part unspecified	EGFR Mutated Lung Cancer Patients with or without Brain Metastasis, Isocitrate Dehydrogenase (IDH) Mutated WHO Grade 3/4 Recurrent Glioma and Adenoid Cystic Carcinoma (ACC)	JBI-778 Oral Capsule 40 mg daily dose in 21-day continuous cycles Once daily dosing in repeated 21-day cycles. JBI-778 capsule is taken orally with water approximately same time either 1 hour before a meal or 2 hours after a meal	<p>All India Institute of Medical Sciences(AIIMS) ,DELHI</p> <p>Artemis Hospital,HARYANA</p> <p>Erode Cancer Centre Private Limited,TAMIL NADU</p> <p>HCG Manavata Cancer Centre,MAHARASHTRA</p> <p>Kiran Super Multi-Speciality Hospital.,GUJARAT</p> <p>Oncoville Cancer Hospital and Research Center,KARNATAKA</p> <p>SunAct Cancer Institute Pvt Ltd.,MAHARASHTRA</p> <p>Tata Memorial Center,MAHARASHTRA</p>	View
CTRI/2024/08/072275	A study to assess the safety and effectiveness of a novel treatment regimen for advanced lung cancer with an uncommon genetic mutation	Interventional	<p>Total: Not Applicable</p> <p>Indian: Open to Recruitment</p>	Malignant neoplasm of overlappingsites of bronchus and lung	Histologically or cytologically confirmed locally advanced or metastatic non-squamous NSCLC with EGFR exon 20 insertion mutation on tissue demonstrated by Next Generation Sequencing or Polymerase Chain Reaction	Chemotherapy and Cetuximab	<p>Christian Medical College, Vellore,TAMIL NADU</p> <p>Mahamana Pandit Madan Mohan Malviya Cancer Center and Homi Bhabha Cancer Hospital,UTTAR PRADESH</p>	View
	A Study of LY3537982 in Patients with Lung Cancer	Interventional	<p>Total: Open to Recruitment</p> <p>Indian: Open to Recruitment</p>	Malignant neoplasm of unspecified part of bronchus or lung	<p>1. Histologically or cytologically confirmed NSCLC with Stage IIIB-IIIC or Stage IV disease, not suitable for curative intent radical surgery or radiation therapy.</p> <p>2. Part B: the histology of the tumor must be predominantly non-squamous (in line with pemetrexed label).</p>	Experimental: Part A: LY3537982 plus Pembrolizumab	All India Institute of Medical Sciences (AIIMS) ,ORISSA	

TRI No.	Public Title	Type of Trial	Recruitment Status	Health Condition	Basic Inclusion criteria (Click on View for more detail of criteria)	Intervention/Drug/Treatment Name	Location	Details of Trails
CTRI/2024/12/077822					3. Must have disease with evidence of KRAS G12C mutation. 4. Must have known programmed death-ligand 1 (PD-L1) expression of Part A: Greater than or equal to 50%, or Part B: 0% to 100%.	Experimental: Part B: LY3537982 plus Pembrolizumab, Pemetrexed, and Platinum	Ashwin Multispeciality Hospital,TAMIL NADU	View
							Grant Medical Foundation " Ruby Hall Clinic,MAHARASHTRA	
							HCG Manavata Cancer Centre ,MAHARASHTRA	
							Hemato Oncology Clinic Ahmedabad,GUJARAT	
							Jawaharlal Institute Of Postgraduate Medical Education And Research (JIPMER) ,PONDICHERRY	
							KLES Dr. Prabhakar Kore Hospital and Medical Research Centre,KARNATAKA	
							Kolhapur Cancer Center Hospital Pvt Ltd,MAHARASHTRA	
							Krishna Vishwa Vidyapeeth (Deemed to be University) ,MAHARASHTRA	
							Lifepoint Multispecialty Hospital ,MAHARASHTRA	
							Mahamana Pandit Madan Mohan Malaviya Cancer Centre (MPMCC) and Homi Bhabha Cancer Hospital (HBCH),UTTAR PRADESH	
							Mahatma Gandhi Cancer Hospital and Research Institute ,ANDHRA PRADESH	
							Nizams Institute of Medical Sciences (NIMS) ,TELANGANA	
							Pacific Medical College and Hospital,RAJASTHAN	
							Regional Cancer Centre " Thiruvananthapuram,KERALA	
							Sahyadri Super Speciality Hospital ,MAHARASHTRA	
							SRV Agadi Hospital and Research Centre ,KARNATAKA	
Tata Memorial Hospital,MAHARASHTRA								
CTRI/2024/10/075387	A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer	Interventional	Total: Open to Recruitment Indian: Not Yet Recruiting	Malignant neoplasm of unspecified part of bronchus or lung	1. Squamous or non-squamous Stage IV NSCLC not amenable to curative surgery or radiation 2. Absence of sensitizing EGFR mutations (including, but not limited to, exon 19 deletion and exon 21 L858R, exon 21 L861Q, exon 18 G719X, and exon 20 S768I mutations) and ALK and ROS1 rearrangements. 3. Tumor PD L1 TC expression 50 percentage as determined using the VENTANA PD-L1 (SP263)	Experimental Arm-1 Volrustomig plus histology-specific chemotherapy (carboplatin plus either pemetrexed or paclitaxel) via IV infusion	Bharat Hospital and Institute of Oncology,KARNATAKA	View
							CARE Hospitals,TELANGANA	
							HCG Manavata Cancer Centre ,MAHARASHTRA	
							KIMS - KINGSWAY HOSPITALS,MAHARASHTRA	
							Mahamana Pandit Madan Mohan Malviya Cancer Centre,UTTAR PRADESH	
							Netaji Subhas Chandra Bose Cancer Hospital,WEST BENGAL	
							NH-Rabindranath Tagore International Institute of Cardiac Sciences,WEST BENGAL	
							Radhakrishna Multispeciality Hospital,KARNATAKA	
							Rajiv Gandhi Cancer Institute and Research Centre,DELHI	
							Vardham Mahavir Medical College and Safdarjung Hospital,DELHI	
CTRI/2024/11/076528	COMPARISON OF ENDOBRONCHIAL ULTRASOUND AND PET-CT WITH SURGICAL HISTOPATHOLOGY IN NODAL STAGING OF NON-SMALL CELL LUNG CANCER IN PATIENTS	Interventional	Total: Not Applicable Indian: Not Yet Recruiting	Malignant neoplasm of lower respiratory tract, part unspecified	All NSCLC lung undergoing surgery after mediastinal nodal evaluation	PET-CT	AIIMS, New Delhi,DELHI	View
							Endobronchial USG	
	Evixapodlin Monotherapy in Advanced Non-Small Cell Lung Cancer	Interventional	Total: Not Yet Recruiting Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	1. Regionally advanced, unresectable, histologically or cytologically documented, Stage IIIB or Stage IV NSCLC, who have recurrence or progression during or after one prior platinum containing chemotherapy regimen for advanced or metastatic disease. 2. At least one measurable non central nervous system NSCLC lesion qualifying as measurable disease per RECIST	Evixapodlin	ACE hospital and research centre,MAHARASHTRA	View
							All India Institute of Medical Sciences,UTTARANCHAL	
							All India Institute of Medical Sciences,BIHAR	

TRI No.	Public Title	Type of Trial	Recruitment Status	Health Condition	Basic Inclusion criteria (Click on View for more detail of criteria)	Intervention/Drug/Treatment Name	Location	Details of Trails
CTRI/2025/05/086220					based on assessment by central radiologist 3. Tumor PD L1 high expression with one of the prespecified commercial IHC assays above the defined threshold		All India Institute of Medical Sciences,DELHI Apollo Spectra Hospital ,UTTAR PRADESH Arignar Anna Memorial cancer Hospital and Research Institute ,TAMIL NADU Artemis hospital,HARYANA Basavatarakma Indo-American Cancer Hospital & Research Institute ,TELANGANA Chittaranjan National Cancer Institute,WEST BENGAL CIMETS Inamdar Multispeciality Hospital, Pune,MAHARASHTRA Deenanath Mangeshkar Hospital & Research Center,MAHARASHTRA Homi Bhabha Cancer Hospital & Research Centre,ANDHRA PRADESH Indraprastha Apollo Hospitals,DELHI Institute of Medical Sciences,UTTAR PRADESH Mahamana Pandit Madan Mohan Malviya Cancer Center ,UTTAR PRADESH Meenakshi Mission Hospital & Research Centre,TAMIL NADU MNJ Institute of Oncology& Regional Cancer Center,TELANGANA Spandana Oncology Centre ,KARNATAKA Sri Ram Cancer & super specialty Centre, Mahatma Gandhi Medical College & hospital,RAJASTHAN Swami Harshankranand Ji Hospital & Research Centre,UTTAR PRADESH Tata Memorial Centre ,MAHARASHTRA VMMC and Safdarjung Hospital,DELHI	View
CTRI/2024/12/078579	A study to examine pharmacokinetics, effectiveness, and safety of BAT3306 plus chemotherapy and compare with EU-Keytruda® and US-Keytruda® in participants aged greater than or equal to 18 years with Stage IV non squamous non-small cell lung cancer	Interventional	Total: Open to Recruitment Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	1. Stage IV non squamous non-small cell lung cancer 2. Tumors without EGFR mutation/ROS1 rearrangement /ALK rearrangement.	BAT3306, EU-Keytruda®, and US-Keytruda®	Cancer Relief Society's RST Regional Cancer Hospital and Research Centre,MAHARASHTRA Chittaranjan National Cancer Institute ,WEST BENGAL Chopada Medicare and research centre Pvt Ltd,MAHARASHTRA Dr. Ram Manohar Lohia Institute of Medical Sciences,UTTAR PRADESH GBH memorial cancer hospital,RAJASTHAN HCG Manavata Cancer Centre,MAHARASHTRA Hemato Oncology Clinic Ahmedabad Pvt Ltd,GUJARAT K R Hospital ,KARNATAKA KIMS- Kingsway Hospitals, SPANV Medisearch Lifesciences Private Limited,MAHARASHTRA Narayan Multispeciality Hospital (Unit of Narayan Hrudayalaya Limited),GUJARAT National Cancer Institute,MAHARASHTRA Nirmal Hospital Pvt Ltd,GUJARAT Regional cancer centre,KERALA Sparsh Hospitals & Critical Care Private limited,ORISSA State Cancer Institute, Indira Gandhi Institute of Medical Science,BIHAR Tata Memorial hospital,MAHARASHTRA	View
	A Phase 3 study of MK-2870 Versus Pemetrexed and Carboplatin Combination Therapy in Participants With	Interventional	Total: Open to Recruitment	Malignant neoplasm of upper respiratory tract, part unspecified	1. advanced-stage nonsquamous NSCLC 2. tumor activating EGFR mutation, exon 19del, L858R, G719X,S768I, or L861Q	MK2870	AIIMS, New Delhi,DELHI	

TRI No.	Public Title	Type of Trial	Recruitment Status	Health Condition	Basic Inclusion criteria (Click on View for more detail of criteria)	Intervention/Drug/Treatment Name	Location	Details of Trails
CTRI/2024/12/078693	Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC)		Indian: Open to Recruitment					View
							Artemis Hospitals,HARYANA	
							Indraprastha Apollo Hospitals,DELHI	
							Kokilaben Dhirubhai Ambani Hospital,MAHARASHTRA	
							Rajiv Gandhi Cancer Institute And Research Centre,DELHI	
							Tata Memorial Centre,MAHARASHTRA	
CTRI/2025/03/082809	Improving Performance Status (General condition) in Advanced Lung cancer with chemotherapy and Immunotherapy	Interventional	Total: Not Applicable	Malignant neoplasm of unspecifiedpart of bronchus or lung	1.Histologically or cytologically confirmed NSCLC 2. Stage 4 or stage 3B or 3C as per AJCC 8th edition which is not amenable for curative intent treatment	Nivolumab 20 mg + Low dose chemotherapy (Paclitaxel and Carboplatin)	ALL INDIA INSTITUTE OF MEDICAL SCIENCES,DELHI	View
			Indian: Not Yet Recruiting				Tata Memorial Centre,MAHARASHTRA	
CTRI/2025/01/079282	A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants with Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)	Interventional	Total: Open to Recruitment	Malignant neoplasm of unspecifiedpart of bronchus or lung	1. Untreated metastatic NSCLC 2. Absence of tumor activating EGFR mutations and absence of ALK gene rearrangements	GME751	Apex Wellness Hospital,MAHARASHTRA	View
			Indian: Open to Recruitment					
							Apollo Hospitals,KARNATAKA	
							Department of Pulmonary Medicine, S. P. Medical College and AG of Hospitals,RAJASTHAN	
							Dr B L Kapur Memorial Hospital,DELHI	
							HCG Manavata Cancer Centre,MAHARASHTRA	
							Healthcare Global Enterprises Limited,KARNATAKA	
							Hemato Oncology Clinic Ahmedabad Pvt. Ltd.,GUJARAT	
							KLES Dr Prabhakar Kore Hospital and Medical Research Centre,KARNATAKA	
							LMMFs Deenanath Mangeshkar Hospital and Research center,MAHARASHTRA	
							Mahamana Pandit Madan Mohan Malaviya Cancer Centre,UTTAR PRADESH	
							Marathwada Regional Cancer Center and Research Institute,,MAHARASHTRA	
							Max Super Speciality Hospital, Saket (A Unit of Devki Devi Foundation),DELHI	
							National Cancer Institute,MAHARASHTRA	
							Nizams Institute of Medical Sciences,,TELANGANA	
							Noble Hospital Pvt Ltd,MAHARASHTRA	
							P D Hinduja Hospital and Medical Research Centre,MAHARASHTRA	
							Sir Ganga Ram Hospital,DELHI	
							Sparsh Hospital and Critical Care (P) Ltd.,,ORISSA	
							State Cancer Institute, Indira Gandhi Institute of Medical Sciences,BIHAR	
	Sujan Surgical Cancer Hospital and Amravati Cancer Foundation,MAHARASHTRA							
	Tata Memorial Centre,MAHARASHTRA							
	The Gujarat Cancer & Research Institute (M.P. Shah Cancer Hospital),GUJARAT							
CTRI/2025/03/082306	Study of Eftilagimod Alfa (Efti) in Combination with Pembrolizumab and Chemotherapy Versus Placebo in Combination with Pembrolizumab and Chemotherapy in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC)(TACTI-004)	Interventional	Total: Not Yet Recruiting	Malignant neoplasm of unspecifiedpart of bronchus or lung	TACTI-004, a double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell lung cancer (NSCLC) receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (PD-1 antagonist) and chemotherapy 1. (stage IIIB/C or stage IV) non-small cell lung cancer (NSCLC) 2. A participant of childbearing potential (POCBP) is eligible if they are not pregnant	efti + Standard of Care arm Combination of efti, pembrolizumab (KEYTRUDA®) and histology-based platinum doublet chemotherapy	All India Institute of Medical Sciences,ORISSA	View
			Indian: Not Yet Recruiting					
							Cancare Foundation The Voluntary Health Services,TAMIL NADU	
							Chittaranjan National Cancer Institute,WEST BENGAL	
							Geri Care Hospitals,TAMIL NADU	
							Healthcare Global Enterprises Limited,KARNATAKA	

TRI No.	Public Title	Type of Trial	Recruitment Status	Health Condition	Basic Inclusion criteria (Click on View for more detail of criteria)	Intervention/Drug/Treatment Name	Location	Details of Trails
							<p>Mahamana Pandit Madan Mohan Malaviya Cancer Centre,UTTAR PRADESH</p> <p>Maulana Azad Medical College Associated Lok Nayak Hospital,DELHI</p> <p>R.K. Birla Cancer Centre, SMS Medical College and Hospital,RAJASTHAN</p> <p>Regional Cancer Centre,KERALA</p> <p>Sunact Cancer Institute,MAHARASHTRA</p>	
CTRI/2025/02/079987	Comparing Reduced Dose Lorlatinib to Crizotinib as First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer	Interventional	Total: Not Applicable Indian: Not Yet Recruiting	Diseases of the respiratory system	1. non-small cell lung carcinoma with ALK positive 2. Patients who have received one or more cycles of chemotherapy while awaiting the results of molecular testing, i.e., before the results of the ALK testing are available are eligible for this study	Reduced-dose Lorlatinib.	<p>Mahamana Pandit Madan Mohan Malaviya Cancer centre,UTTAR PRADESH</p> <p>Tata Memorial Hospital ,MAHARASHTRA</p>	View
CTRI/2025/04/084907	Comparing the relief given by Syrup Methadone with the Tablet Morphine for the treatment of shortness of breath, pain and improving quality of life in Lung Cancer patients.	Interventional	Total: Not Applicable Indian: Not Yet Recruiting	<p>Malignant neoplasm of lower lobe,bronchus or lung</p> <p>Malignant neoplasm of main bronchus</p> <p>Malignant neoplasm of middle lobe,bronchus or lung</p> <p>Malignant neoplasm of overlappingsites of bronchus and lung</p> <p>Malignant neoplasm of pleura</p> <p>Malignant neoplasm of unspecifiedpart of bronchus or lung</p> <p>Malignant neoplasm of upper lobe,bronchus or lung</p>	1. All the patients diagnosed with Lung cancer with age greater than 18 years. 2. Patients with Dyspnoea of MMRC grade greater than	Drug- Syrup Methadone	<p>Dr.B.R.Ambedkar Institute Rotary Cancer Hospital,DELHI</p> <p>National Cancer Institute,HARYANA</p>	View
CTRI/2025/04/085846	A Compare Efficacy and Safety study of CT-P51 and Keytruda in Patients with Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer.	Interventional	Total: Open to Recruitment Indian: Open to Recruitment	Malignant neoplasm of upper lobe,bronchus or lung	1. metastatic nsNSCLC with confirmed PD-L1 expression level in whom EGFR mutation and ALK rearrangement-directed therapy is not indicated will be considered for enrollment. 2. Patient must agree to use acceptable birth control methods throughout the study 3.A man or woman is of childbearing potential if, in the opinion of the investigator, they are biologically capable of having children and are sexually active.	CT-P51	<p>Asha Hospitals and Research centre,KARNATAKA</p> <p>Bhagwan Mahaveer Cancer Hospital & Research Center,,RAJASTHAN</p> <p>CHITTARANJAN NATIONAL CANCER INSTITUTE,WEST BENGAL</p> <p>Deenanath Mangeshkar Hospital and Research Center, ,MAHARASHTRA</p> <p>Dept. of PCCM, Pt. B.D Sharma ,HARYANA</p> <p>KLES Dr. Prabhakar Kore Hospital and Medical Research Centre, ,KARNATAKA</p> <p>Netaji Subhas Chandra Bose Cancer Hospital, ,WEST BENGAL</p> <p>Nirmal Hospital Pvt. Ltd. ,GUJARAT</p> <p>R.K. Birla Cancer center, SMS Medical College & Hospital,RAJASTHAN</p> <p>S.P. Medical College & AG of Hospitals,RAJASTHAN</p> <p>Spandana Oncology ,KARNATAKA</p> <p>Tata Memorial Centre, ,MAHARASHTRA</p> <p>Unique Hospital Multispeciality and Research Institute,GUJARAT</p> <p>Vardhman Mahavir Medical College & Safdarjung Hospital,,DELHI</p>	View
	Study to evaluate efficacy, safety, immunogenicity and	Interventional	Total: Not Applicable	Malignant neoplasm of	Patients must have experienced disease recurrence or progression after one first	Lupin Nivolumab (LUBT022)	Acharya Harihar Postgraduate Institute of Cancer,ORISSA	

TRI No.	Public Title	Type of Trial	Recruitment Status	Health Condition	Basic Inclusion criteria (Click on View for more detail of criteria)	Intervention/Drug/Treatment Name	Location	Details of Trails
CTRI/2025/03/083471	pharmacokinetics of Lupin Nivolumab (LUBT022) with Innovator Nivolumab of Patients with locally advanced or metastatic non-small cell lung cancer		Indian: Not Yet Recruiting	unspecifiedpart of bronchus or lung	line therapy Patients must have received at least 2 cycles of chemotherapy Patients who received adjuvant neoadjuvant or definitive chemoradiation therapy within 6 months Patients with recurrent disease greater than 6 months Presence of at least one measurable target lesion as per RECIST criteria version 1.1		AIIMS Bhubaneshwar,ORISSA	View
							Amerix Cancer Hospital,DELHI	
							Amrita Institute of Medical Sciences,KERALA	
							Ashwin Multispeciality Hospital,TAMIL NADU	
							BGS Global Institute of Medical Sciences ,KARNATAKA	
							Binayak Multi Speciality Hospital,WEST BENGAL	
							Charnock Hospital,WEST BENGAL	
							Chittaranjan National Cancer Institute,WEST BENGAL	
							DNS Hospital Pvt. Ltd ,MADHYA PRADESH	
							ESIC Medical College & Hospital,HARYANA	
							Fortis Hospital Noida,UTTAR PRADESH	
							HCG Cancer Center,MAHARASHTRA	
							HCG Cancer Centre,ANDHRA PRADESH	
							HCG City Cancer Centre,ANDHRA PRADESH	
							HCG Manavata Cancer Center,MAHARASHTRA	
							Hemato Oncology Clinic Ahmedabad Pvt. Ltd.,GUJARAT	
							Indira Gandhi Institute of Medical Science,BIHAR	
							Jawaharlal Nehru Cancer Hospital and Research Centre,MADHYA PRADESH	
							Kailash Cancer Hospital and Research Centre,GUJARAT	
							Kainos Super Speciality Hospital,HARYANA	
							KIMS-Kingsway Hospitals ,MAHARASHTRA	
							Kiran Multi Super Speciality Hospital and Research Center ,GUJARAT	
							KLEs Dr. Prabhakar Kore Hospital and Medical Research Centre,KARNATAKA	
							Life Point Multispecialty Hospital,MAHARASHTRA	
							Lifeline Diagnostic Centre Cum Nursing Home,WEST BENGAL	
							Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital,UTTAR PRADESH	
							Mahatma Gandhi Cancer Centre,ANDHRA PRADESH	
							Mahatma Gandhi Medical College and Hospital,RAJASTHAN	
							Meenakshi Mission Hospital & Research Centre,TAMIL NADU	
							MGM Medical College and Hospital,MAHARASHTRA	
							MNJ Institute of Oncology and Regional Cancer Center,TELANGANA	
							MOC, Cancer Care& Research centre ,MAHARASHTRA	
							Narayana cancer center,BIHAR	
							Nizam's Institute of Medical Science,TELANGANA	
							Oncowin Cancer Center,GUJARAT	
							PP Maniya Hospital Private LTD,GUJARAT	
							R K Birla Cancer Center SMS Medical College,RAJASTHAN	
							Radhakrishna Multispeciality Hospital And IVF Center,KARNATAKA	

TRI No.	Public Title	Type of Trial	Recruitment Status	Health Condition	Basic Inclusion criteria (Click on View for more detail of criteria)	Intervention/Drug/Treatment Name	Location	Details of Trails
							Rajiv Gandhi Government General Hospital Madras Medical College,TAMIL NADU Rajkot Cancer Society,GUJARAT Sanjeevani CBCC USA Cancer Hospital,CHHATTISGARH Sankalp Specialty Hospital,MAHARASHTRA Sarder Patel Medical College and Hospital,RAJASTHAN Seth Nandlal Dhoot Hospital,MAHARASHTRA Shalby Hospital,GUJARAT Shashwat Haemato Onco Assocaites,GUJARAT Spandana Oncology Centre,KARNATAKA Sparsh Hospital & Critical care Pvt. Ltd,ORISSA SRM Medical College Hospital and Research Center ,TAMIL NADU Stanley Hospital and Medical College ,TAMIL NADU Super speciality govt medical college,JAMMU & KASHMIR Swami Harshankaranand Ji Hospital and Research Centre,UTTAR PRADESH Tamil Nadu Government Multi Super Speciality Hospital,TAMIL NADU Taran Onco Care,MADHYA PRADESH Tata Memorial Hospital,MAHARASHTRA Unique Hospital Multispeciality and Research Insititute,GUJARAT VMMC and safdarjung Hospital,DELHI Yashoda Super Specialty Hospital,TELANGANA	
CTRI/2025/11/097595	A Study Comparing Two First-Time Treatment Combinations for Patients with Extensive-Stage Small Cell Lung Cancer	Interventional	Total: Open to Recruitment Indian: Not Yet Recruiting	Malignant neoplasm of overlappingsites of bronchus and lung	1. Participants must have histologically or cytologically documented SCLC Participants must have extensive stage disease Stage IV or T3 -4 due to multiple lung nodules that are too extensive or tumor or nodal volume that is too large to be encompassed in a tolerable radiation plan Participants must be suitable to receive platinum-based chemotherapy regimen as well as anti PD L 1 based regimens as per locally approved drug labels and institutional guidelines	Arm A: BMS 986489 FDC (BMS 986012 + Nivolumab) + Carboplatin + Etoposide Arm B: Atezolizumab + Carboplatin + Etoposide	Meenakshi Mission Hospital & Research Centre,TAMIL NADU All India Institute of Medical Sciences,DELHI Mahamana Pandit Madan Mohan Malviya Cancer Centre,UTTAR PRADESH Manipal Hospital,KARNATAKA Netaji Subhas Chandra Bose Cancer Hospital,WEST BENGAL	View
CTRI/2026/01/100675	A clinical trial involving a new drug combination for treatment of advanced lung cancer with KRAS G12C mutation	Interventional	Total: Open to Recruitment Indian: Not Yet Recruiting	Malignant neoplasm of unspecifiedpart of bronchus or lung	1. Histologically or cytologically confirmed diagnosis of non-squamous NSCLC 2. Locally advanced or metastatic disease 3. No prior systemic anti-cancer therapy given for advanced or metastatic diseas 4. Evidence of KRAS G12C mutation via tumor tissue and or ctDNA documented by Sponsor-approved laboratory testing 5. Participants with brain metastases are eligible for enrollment including those with untreated brain metastases. Brain metastases must be asymptomatic and not in need of immediate local therapy. Any untreated brain metastases must be less than or equal to 20 mm in diameter.	Arm A: Adagrasib + Pembrolizumab + Pemetrexed + Cisplatin/Carboplatin	Apollo Hospital Enterprise Limited,ANDHRA PRADESH Basavatarakam Indo American Cancer Hospital,TELANGANA Dr. B. R. Ambedkar Institute Rotary Cancer Hospital,DELHI Hemato Oncology Clinic Ahmedabad Pvt. Ltd.,GUJARAT Institute of Medical Sciences and SUM Hospital,ORISSA Mahamana Pandit Madan Mohan Malaviya Cancer Centre ,UTTAR PRADESH Marengo CIMS Hospital Pvt Ltd,GUJARAT Meenakshi Mission Hospital and Research Centre,TAMIL NADU Narayana Superspeciality Hospital,WEST BENGAL	View

TRI No.	Public Title	Type of Trial	Recruitment Status	Health Condition	Basic Inclusion criteria (Click on View for more detail of criteria)	Intervention/Drug/Treatment Name	Location	Details of Trails
							Netaji Subhas Chandra Bose Cancer Hospital,WEST BENGAL Rajiv Gandhi Cancer Institute and Research Center,DELHI Regional Cancer Centre, Thiruvananthapuram,KERALA Tata Memorial Centre,MAHARASHTRA Vardhman Mahavir Medical College & Safdarjung Hospital,DELHI Yashoda Healthcare Services Private Limited,TELANGANA	
CTRI/2025/02/080765	A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Interventional	Total: Open to Recruitment Indian: Not Yet Recruiting	Malignant neoplasm of unspecified part of bronchus or lung	Histologically or cytologically confirmed non squamous NSCLC. Must have evidence of documented pre existing EGFRm information EGFRm known to be associated with epidermal growth factor receptor EGFR tyrosine kinase inhibitor TKIs sensitivity Ex19de, L858R, G719X, S768I, or L861Q, either alone or in combination with other EGFR mutations, which may include T790M. Documented extra cranial radiologic progression on prior osimertinib monotherapy as most recent line of treatment in the adjuvant, locally advanced, or metastatic setting. Less than or equal to less than 2 prior lines of EGFR TKIs osimertinib is the only permitted prior third generation EGFR TKI.	Dato-DXd Osimertinib	All India Institute of Medical Sciences,ORISSA Basavataarakam Indo American Cancer Hospital & Research Institute ,TELANGANA Bhaktivedanta Hospital and Research Institute,MAHARASHTRA Bharath Hospital and Institute of Oncology ,KARNATAKA GBH General Hospital & GBH Memorial Cancer Hospital ,RAJASTHAN Grant Medical Foundation Ruby Hall Clinic ,MAHARASHTRA Jharkhand Cancer Center,JHARKHAND Kolhapur Cancer Centre (KCC) ,MAHARASHTRA Mahamana Pandit Madan Mohan Malaviya Cancer Centre,UTTAR PRADESH Regional Cancer Centre, Medical College Campus ,KERALA Sanjeevani CBCC USA Cancer Hospital ,CHHATTISGARH Sujan surgical cancer hospital and ACF,MAHARASHTRA Thangam Hospital and Thangam Cancer Center ,TAMIL NADU	View
CTRI/2025/02/081029	A Study to Test Chemotherapy with Low-Dose Immunotherapy Before Surgery in Treatable Lung Cancer	Interventional	Total: Not Applicable Indian: Not Yet Recruiting	Malignant neoplasm of lower lobe,bronchus or lung Malignant neoplasm of main bronchus Malignant neoplasm of middle lobe,bronchus or lung Malignant neoplasm of overlappingsites of bronchus and lung Malignant neoplasm of unspecified part of bronchus or lung Malignant neoplasm of upper lobe,bronchus or lung	<input type="checkbox"/> Participants with histologically confirmed Stage 2A greater than or equal to 4 cm 2B 3A 3B N2 NSCLC as per the 8th American Joint Committee on Cancer AJCC with disease that is considered resectable 2 Subjects must be treatment naive and have an Eastern Cooperative Oncology Group ECOG performance status PS 0 to	3 cycles of neoadjuvant chemotherapy(Taxane/Pemetrexed and Platinum) with low dose Immunotherapy (Nivolumab40mg)	Tata Memorial Centre,MAHARASHTRA Thangam Hospital,TAMIL NADU	View
	A Global Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato DXd) for Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer	Interventional	Total: Open to Recruitment Indian: Not Yet Recruiting	Malignant neoplasm of unspecified part of bronchus or lung	Histologically or cytologically documented nonsquamous NSCLC. 3_Stage IIIB or IIIC or Stage IV metastatic NSCLC or recurrent NSCLC not amenable to curative surgery or definitive chemoradiation at the time of randomisation. 4_Participants must not have received prior EGFR TKIs or other systemic therapy for Stage IIIB, IIIC or IV NSCLC. 5_The tumour harbors 1 of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del or L858R), either alone or in combination with other EGFR mutations	Experimental Arm-1 Osimertinib in combination with Datopotamab Deruxtecan	All India Institute of Medical Sciences ,DELHI Apollo Multispecialty Hospitals Limited,WEST BENGAL Bharat Hospital and Institute of Oncology,KARNATAKA CARE Hospitals,TELANGANA	

TRI No.	Public Title	Type of Trial	Recruitment Status	Health Condition	Basic Inclusion criteria (Click on View for more detail of criteria)	Intervention/Drug/Treatment Name	Location	Details of Trails
CTRI/2025/04/083797					Combination with other EGFR mutations		HCG Manavata Cancer Centre,MAHARASHTRA Health Care Global Enterprises Limited,KARNATAKA Kailash Cancer Hospital and Research Center,GUJARAT KIMS KINGSWAY HOSPITAL,MAHARASHTRA Mahamana Pandit Madan Mohan Malaviya Cancer Centre,UTTAR PRADESH Rajiv Gandhi Cancer Institute and Research Centre,DELHI Vardhman Mahavir Medical College and Safdarjung Hospital,DELHI	View
CTRI/2025/07/091106	Study on Olomorasib in Lung Cancer Patients	Interventional	Total: Open to Recruitment Indian: Not Yet Recruiting	Malignant neoplasm of unspecified part of bronchus or lung	1. Histological or cytological confirmation of NSCLC. 1.1 Part A 1.1.1 Clinical Stage II-III B (N2) treated with presurgical chemoimmunotherapy, with residual tumor present at time of surgery. Patients with a pathologic complete response are not eligible. 2. Pathologic Stage II-III B (N2) NSCLC treated with initial upfront resection. 2.1 Part B 2.1.1 Clinical Stage III, unresectable NSCLC, without progression on concurrent platinum-based chemoradiotherapy. 3. Must have disease with evidence of KRAS G12C mutation 4. Must have known programmed death-ligand 1 (PD-L1) expression	Part A: Olomorasib plus Pembrolizumab Part B: Olomorasib plus Durvalumab	Deenanath Mangeshkar Hospital and Research Centre,MAHARASHTRA Galaxy Superspeciality Hospital,MAHARASHTRA Hemato Oncology Clinic Ahmedabad Pvt. Ltd,GUJARAT Mahamana Pandit Madan Mohan Malaviya Cancer Centre (MPMMCC) and Homi Bhabha Cancer Hospital (HBCH),UTTAR PRADESH Malabar Cancer Centre,KERALA Medipoint Hospitals Pvt. Ltd.,MAHARASHTRA Pacific Medical College & Hospital,RAJASTHAN Rajiv Gandhi Government General Hospital Madras Medical College,TAMIL NADU Regional Cancer Centre College Campus,KERALA Savera Cancer & Multispeciality Hospital,BIHAR Sir H.N. Reliance Foundation Hospital and Research Centre,MAHARASHTRA Thangam Cancer Center and Research Institute,TAMIL NADU	View
CTRI/2025/06/089071	Perfecting the best treatment choices for non-small cell lung cancer patients using advanced genetic testing.	Interventional	Total: Not Yet Recruiting Indian: Not Yet Recruiting	Malignant neoplasm of overlapping sites of bronchus and lung	Patients with confirmed non-small cell lung cancer based on pathological or histological analysis. Patients who have undergone NGS testing to identify actionable mutations. Patients receiving targeted therapies or	pharmacist intervention for NGS testing group	HCG Cancer Hospital ,KARNATAKA	View
CTRI/2025/06/089098	A study to find out if giving low dose cancer drug nivolumab with chemotherapy before surgery is safe and helpful for people with operable lung cancer	Interventional	Total: Not Applicable Indian: Not Yet Recruiting	Malignant neoplasm of unspecified part of bronchus or lung	Pathological diagnosis of NSCLC Stage IB to IIIB T3N2 irrespective of PDL1 status Being considered for neoadjuvant treatment followed by surgery after evaluation by MDT Complete surgical removal should be deemed achievable including surgical fitness ECOG PS 0 to 1	Nivolumab	Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh,CHANDIGARH	View
CTRI/2025/10/096678	Two clinical trials for people with advanced lung cancer that has a KRAS G12C mutation: one is a Phase 2 study testing adagrasib alone and with pembrolizumab, and the other is a Phase 3 study comparing the combination of adagrasib and pembrolizumab to pembrolizumab alone.	Interventional	Total: Open to Recruitment Indian: Not Yet Recruiting	Malignant neoplasm of unspecified part of bronchus or lung	Phase 3: Histologically confirmed diagnosis of unresectable or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS more than equal to 50 percentage. • Phase 3: Presence of evaluable or measurable disease per RECIST • Phase 3: CNS Inclusion - Based on screening brain imaging, patients must have one of the following: 1. No evidence of brain metastases 2. Untreated brain metastases not needing immediate local therapy 3. Previously treated brain metastases not needing immediate local therapy	Adagrasib + pembrolizumab	Amrita Institute of Medical Sciences,KERALA Basavatarakam Indo American Cancer Hospital & Research Institute (BIACH&RI),TELANGANA Hemato Oncology Clinic Ahmedabad Pvt. Ltd,GUJARAT Indraprastha Apollo Hospitals,DELHI KLES Dr Prabhakar Kore Hospital & Medical Research Centre,KARNATAKA Mahamana Pandit Madan Mohan Malaviya Cancer Centre,UTTAR PRADESH Marathwada Cancer Hospital and Research Institute,MAHARASHTRA Marengo CIMS Hospital Pvt. Ltd.,GUJARAT Meenakshi Mission Hospital & Research Centre,TAMIL NADU	View

TRI No.	Public Title	Type of Trial	Recruitment Status	Health Condition	Basic Inclusion criteria (Click on View for more detail of criteria)	Intervention/Drug/Treatment Name	Location	Details of Trails
							Mysore Medical College and Research Institute,KARNATAKA Narayana Superspeciality Hospital ,WEST BENGAL Netaji Subhas Chandra Bose Cancer Hospital & Research Institute,WEST BENGAL Nirmal Hospital Pvt. Ltd.,GUJARAT R.K. Birla Cancer Center, S.M.S Medical College & Attached Hospital,RAJASTHAN State Cancer Institute Indira Gandhi Institute of Medical Sciences,BIHAR Tata Memorial Centre,MAHARASHTRA	
CTRI/2025/06/088853	A 6 Week Gentle Exercise Program to Improve Fitness, Breathing, and Well being in Lung Cancer Patients During Radiotherapy	Interventional	Total: Not Applicable Indian: Not Yet Recruiting	Neoplasms	1) Adults diagnosed with lung cancer and undergoing radiotherapy Stage I-III. 2) Clinically stable, with no acute exacerbation of symptoms in the past 4 weeks. 3) Currently undergoing radiotherapy.	STRUCTURED LOW INTENSITY CIRCUIT TRAINING PROGRAM FOR PATIENTS WITH LUNG CANCER UNDERGOING RADIOTHERAPY	Rashtrasant Janardhan Swami Hospital and Cancer Research Center Kokamthan, Kopargaon,MAHARASHTRA	View
CTRI/2025/07/091069	This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non small Cell Lung Cancer With High Levels of PDL1.	Interventional	Total: Open to Recruitment Indian: Not Yet Recruiting	Malignant neoplasm of unspecified part of bronchus or lung	An Open-Label, Randomized, Controlled Phase 3 Study of Sigvotatug Vedotin in Combination with Pembrolizumab Compared with Pembrolizumab Monotherapy as First-Line Treatment in Participants with PD-L1 High, more than 50 percent of Tumor Cells Expressing PDL1, Locally Advanced, Unresectable, or Metastatic Non Small Cell Lung Cancer. Participants must meet the following criteria- -Have pathologically confirmed Stage IIIB or IIIC NSCLC and not be a candidate for surgical resection or definitive chemoradiation, or Stage IV NSCLC per the AJCC Staging Manual, Version 8.0 and the UICC Staging System, Eighth edition. -Participants with non-squamous histology must have documented negative test results for EGFR, ALK, and ROS1 AGAs and no known AGAs in NTRK, BRAF, RET, MET, or other AGAs with approved front-line therapies per local standard of care. -Large cell neuroendocrine carcinoma is excluded. -Candidate for treatment with pembrolizumab monotherapy per local guidelines. 2. Tumor has PD-L1 expression in more than 50 percent of tumor cells as determined by local testing	Sigvotatug vedotin	Bhakti Vedanta Hospital and Research Institute,MAHARASHTRA Dr B.L. Kapur Memorial Hospital,DELHI Fortis Hospital,DELHI Sahyadri Super Speciality Hospital,MAHARASHTRA Spandana Oncology Centre,KARNATAKA Tata Memorial Hospital,MAHARASHTRA Venkateshwar Hospital,DELHI	View
CTRI/2025/07/090716	Effectiveness and safety study of Inj. Pembrolizumab in patients with Lung cancer	Interventional	Total: Not Applicable Indian: Not Yet Recruiting	Malignant neoplasm of unspecified part of bronchus or lung	Histologically or cytologically confirmed diagnosis of Non Squamous type of metastatic NSCLC. 3. Tumor with PD-L1 positive and without any EGFR, ALK positive mutations. 4. Have not received prior systemic treatment for their advanced/metastatic NSCLC.	Hetero-Pembrolizumab (Hetero Biopharma Ltd, India)	Basavatarakam Indo-American Cancer Hospital and Research Institute,TELANGANA Chittaranjan National Cancer Institute,WEST BENGAL Deenanath Mangeshkar Hospital,MAHARASHTRA Dr. BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences,DELHI HCG City Cancer Centre,ANDHRA PRADESH Indira Gandhi Insitute of Medical Sciences,BIHAR MNJ Institute of Oncology & Regional Cancer Centre,TELANGANA Rajiv Gandhi General Government Hospital.,TAMIL NADU Sparsh Hospital,ORISSA Tamil Nadu Government Multi Super Speciality Hospital,TAMIL NADU Unique Hospital,GUJARAT Vardhman Mahavir Medical College and Safdarjung hospital,DELHI	View
	Safety study of GME751 (Pembrolizumab Biosimilar) for Patients with Melanoma or Non-Small Cell Lung Cancer	Interventional	Total: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	An open-label, multi-center, single arm, rollover study of GME751 (proposed pembrolizumab biosimilar) in participants who are eligible for	GME751	Apex Wellness Hospital,MAHARASHTRA	

TRI No.	Public Title	Type of Trial	Recruitment Status	Health Condition	Basic Inclusion criteria (Click on View for more detail of criteria)	Intervention/Drug/Treatment Name	Location	Details of Trails
CTRI/2025/08/093686			Indian: Not Yet Recruiting		continued pembrolizumab treatment after participation in CGME751A12101 or CGME751A12301 studie		<p>Dr. B. L. Kapur Memorial Hospital,DELHI</p> <p>Mahamana Pandit Madan Mohan Malaviya Cancer Centre,UTTAR PRADESH</p> <p>Nizams Institute of Medical Sciences,TELANGANA</p> <p>P D Hinduja Hospital and Medical Research Centre,MAHARASHTRA</p> <p>Tata Memorial Centre,MAHARASHTRA</p> <p>The Gujarat Cancer & Research Institute (M.P. Shah Cancer Hospital),GUJARAT</p>	View
CTRI/2025/12/099413	A Phase 3 Study comparing Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Platinum-based Chemotherapy in Combination with Pembrolizumab, as First-line Therapy in Participants with Non-Squamous Non-small Cell Lung Cancer	Interventional	Total: Not Yet Recruiting Indian: Not Yet Recruiting	Malignant neoplasm of unspecified part of bronchus or lung	<p>Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Platinum-based Chemotherapy in Combination with Pembrolizumab, as First-line Therapy in Participants with Locally Advanced Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS 50% Non-squamous Non-small Cell Lung Cancer.</p> <p>stologically documented non-squamous locally advanced unresectable or metastatic NSCLC and meets all of the following criteria: Has Stage IV NSCLC disease or Stage IIIB or IIIC disease but is not a candidate for surgical resection or definitive chemoradiation at the time of randomization. Has no known AGAs that have locally available therapies targeting their AGAs in the first-line advanced/metastatic setting. Has no known HER2 mutation based on existing test results. Note: Participants with mixed histology are eligible if adenocarcinoma is the predominant histology. Mixed tumors will be classified based on the predominant cell type.</p>	Trastuzumab Deruxtecan	<p>All India Institute of Medical Sciences,ORISSA</p> <p>Deenanath Mangeshkar Hospital & Research Center,MAHARASHTRA</p> <p>Mazumdar Shaw Medical Center, Narayana Hrudayalaya Limited,KARNATAKA</p> <p>Narayana Superspeciality Hospital,WEST BENGAL</p> <p>Nirmal Hospital Pvt. Ltd.,GUJARAT</p> <p>Tata Memorial Hospital,MAHARASHTRA</p> <p>Yenepoya Medical College Hospital,KARNATAKA</p>	View
CTRI/2025/09/094871	A clinical study to check efficacy and safety of Envafolelimab injection in treatment of lung cancer.	Interventional	Total: Open to Recruitment Indian: Open to Recruitment	Malignant neoplasm of overlapping sites of bronchus and lung	<p>1. Histological and/or cytological diagnosis of resectable Stage IIIA-IIIIB(N2) NSCLC</p> <p>2. Measurable lesion(s) based on the RECIST Version 1.1</p>	Envafolelimab Injection	<p>All India Institute of Medical Sciences,DELHI</p> <p>Apollo Cancer Hospitals, Apollo Hospitals,TELANGANA</p> <p>Apollo Hospitals Ahmedabad,GUJARAT</p> <p>Asian Cancer Institute-ACI Hospitals,MAHARASHTRA</p> <p>Fortis Memorial Research Institute,HARYANA</p> <p>Grant Medical Foundation Ruby Hall Clinic,MAHARASHTRA</p> <p>HCG Cancer Centre,RAJASTHAN</p> <p>HCG City Cancer Centre,ANDHRA PRADESH</p> <p>Kainos Superspeciality Hospital,HARYANA</p> <p>LMMFs Deenanath Mangeshkar Hospital & Research Center ,MAHARASHTRA</p> <p>Malabar Cancer Centre(PGIOSR),KERALA</p> <p>Max Super Speciality Hopsital,DELHI</p> <p>Medanta-The Medicity,HARYANA</p> <p>MOC Cancer Care & Research Centre ,MAHARASHTRA</p> <p>MVR Cancer Centre and Research Institute,KERALA</p> <p>National Cancer Institute,MAHARASHTRA</p> <p>PGIMS Rohtak,HARYANA</p> <p>Regional Cancer Centre,KERALA</p> <p>Sahyadri Super Speciality Hospital,MAHARASHTRA</p> <p>Sankalp Speciality Hospital,MAHARASHTRA</p> <p>Sir Ganga Ram Hospital,DELHI</p>	View

TRI No.	Public Title	Type of Trial	Recruitment Status	Health Condition	Basic Inclusion criteria (Click on View for more detail of criteria)	Intervention/Drug/Treatment Name	Location	Details of Trails
							Sir H N Reliance Foundation Hospital and Research Hospital,MAHARASHTRA SMS Medical College & Attached Hospital,RAJASTHAN SunAct Cancer Institute Pvt Ltd; Tieten Medicity Hospital,MAHARASHTRA The Gujarat Cancer & Research Institute,GUJARAT Vardhman Mahavir Medical College and Safdarjung Hospital,DELHI	
CTRI/2025/09/094928	Comparative Study Between Two Types of Courses of Thoracic Radiotherapy in Stage IV Lung Cancer	Interventional	Total: Not Yet Recruiting Indian: Not Yet	Malignant neoplasm of bronchus and lung	1.Histologically or Cytologically proven Non-Small Cell Lung Cancer 2. Stage IV Lung Cancer, according to AJCC Staging 9th version	20 Gy in 5 consecutive days	IPGME&R and SSKM Hospital ,WEST BENGAL	View
CTRI/2025/11/097084	A trial to learn how safe datopotamab deruxtecan (Dato-DXd) is compared to docetaxel and how well Dato-DXd works in adults with advanced or metastatic TROP2-positive, non-squamous non-small cell lung cancer (NS-NSCLC)	Interventional	Total: Open to Recruitment Indian: Not Yet Recruiting	Malignant neoplasm of upper respiratory tract, part unspecified	Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung17) Participants must have documented negative test results for EGFR (eg, exon 19 deletion or exon 21 L858R, exon 21 L861Q, exon 18 G719X, or exon 20 S768I mutation), ALK, and ROS1 genomic alterations	Experimental Arm Volrustomig	All India Institute of Medical Sciences,DELHI HCG Manavata Cancer Centre,MAHARASHTRA Health Care Global Enterprises Limited,KARNATAKA Netaji Subhash Chandra Bose Cancer Research Institute,WEST BENGAL Tata Memorial Centre,MAHARASHTRA	View
CTRI/2025/12/099294	A Phase 3 Study to Learn About the Study Medicine Called PF-08046054 Versus Docetaxel in Adult Participants With Previously-treated Non-Small-Cell Lung Cancer with Programmed Cell Death Ligand 1 Positive.	Interventional	Total: Open to Recruitment Indian: Not Yet Recruiting	Malignant neoplasm of main bronchus	Histologically or cytologically confirmed diagnosis of locally advanced, unresectable Stage IIIB and IIIC not eligible for definitive chemoradiotherapy or metastatic. Participants with known AGAs (eg, EGFR mutations, ALK translocations, or other relevant actionable mutations) must fulfill the following conditions: - Must have received at least 1 approved AGA-targeted therapy and, in the opinion of the investigator, additional AGA-targeted therapy is not in the best interest of the participant - Received a platinum-based combination therapy for the treatment of metastatic or recurrent disease, or experienced disease progression within 6 months of the last dose of platinum-based chemotherapy in the adjuvant, neoadjuvant, or chemoradiotherapy setting. - May have received PD-1 or PD-L1 monoclonal antibody (concurrently or sequentially with platinum-based chemotherapy).	PF-08046054	Apollo Multispeciality Hospitals Limited,WEST BENGAL Caritas Cancer Institute - Caritas Hospital & Institute Of Health Sciences,KERALA Fortis Hospital,DELHI Rajiv Gandhi Cancer Institute and Research Centre,DELHI Sahyadri Super Speciality Hospital,MAHARASHTRA Tata Memorial Hospital,MAHARASHTRA	View
CTRI/2025/12/099374	Effect of a oral nutritional protein supplement with and without dietary counselling in patients with breast and lung cancer	Interventional	Total: Not Applicable	Malignant neoplasm of breast. Malignant neoplasms of respiratory and intrathoracic organs	Subjects with diagnosed solid tumors (stage 2 and stage 3)	Protimedical an oral Nutritional Supplementary and Dietary counselling	Apollo Speciality Hospital,TAMIL NADU	View